

---

Walker Chandiook & Co LLP

Plot No. 19A, 2nd floor,  
Sector - 16A,  
Noida - 201 301  
Uttar Pradesh, India

T +91 120 485 5999  
F +91 120 485 5902

## Independent Auditor's Report

To the Members of Jubilant Biosys Limited

Report on the Audit of the Financial Statements

### Opinion

1. We have audited the accompanying financial statements of Jubilant Biosys Limited ('the Company'), which comprise the Balance Sheet as at 31 March 2024, the Statement of Profit and Loss (including Other Comprehensive Income), the Statement of Cash Flow and the Statement of Changes in Equity for the year then ended, and notes to the financial statements, including material accounting policy information and other explanatory information.
2. In our opinion and to the best of our information and according to the explanations given to us, the aforesaid financial statements give the information required by the Companies Act, 2013 ('the Act') in the manner so required and give a true and fair view in conformity with the Indian Accounting Standards ('Ind AS') specified under section 133 of the Act read with the Companies (Indian Accounting Standards) Rules, 2015 and other accounting principles generally accepted in India, of the state of affairs of the Company as at 31 March 2024, and its profit (including other comprehensive loss), its cash flows and the changes in equity for the year ended on that date.

### Basis for Opinion

3. We conducted our audit in accordance with the Standards on Auditing specified under section 143(10) of the Act. Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India ('ICAI') together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act and the rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

### Information other than the Financial Statements and Auditor's Report thereon

4. The Company's Board of Directors are responsible for the other information. Other information does not include the financial statements and our auditor's report thereon.

Our opinion on the financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated.



# Walker ChandioK & Co LLP

## Independent Auditor's Report on the Audit of the Financial Statements of Jubilant Biosys Limited for the year ended 31 March 2024 (Cont'd)

The Directors' Report is not made available to us at the date of this auditor's report. We have nothing to report in this regard.

### Responsibilities of Management for the Financial Statements

5. The accompanying financial statements have been approved by the Company's Board of Directors. The Company's Board of Directors are responsible for the matters stated in section 134(5) of the Act with respect to the preparation and presentation of these financial statements that give a true and fair view of the financial position, financial performance including other comprehensive income, changes in equity and cash flows of the Company in accordance with the Ind AS specified under section 133 of the Act and other accounting principles generally accepted in India. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.
6. In preparing the financial statements, the Board of Directors is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

### Auditor's Responsibilities for the Audit of the Financial Statements

7. Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with Standards on Auditing will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.
8. As part of an audit in accordance with Standards on Auditing, specified under section 143(10) of the Act we exercise professional judgment and maintain professional skepticism throughout the audit. We also:
  - Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control;
  - Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Act we are also responsible for expressing our opinion on whether the Company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls;
  - Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management;



# Walker Chandniok & Co LLP

## Independent Auditor's Report on the Audit of the Financial Statements of Jubilant Biosys Limited for the year ended 31 March 2024 (Cont'd)

- Conclude on the appropriateness of Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern; and
  - Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.
9. We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

### Other Matter

10. The financial statements of the Company for the year ended 31 March 2023 were audited by the predecessor auditor, B S R & Co. LLP, Chartered Accountants, who have expressed an unmodified opinion on those financial statements vide their audit report dated 29 May 2023.

### Report on Other Legal and Regulatory Requirements

11. As required by section 197(16) of the Act based on our audit, we report that the Company has paid remuneration to its directors during the year in accordance with the provisions of and limits laid down under section 197 read with Schedule V to the Act.
12. As required by the Companies (Auditor's Report) Order, 2020 ('the Order') issued by the Central Government of India in terms of section 143(11) of the Act we give in the Annexure I, a statement on the matters specified in paragraphs 3 and 4 of the Order, to the extent applicable.
13. Further to our comments in Annexure I, as required by section 143(3) of the Act based on our audit, we report, to the extent applicable, that:
- a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purpose of our audit of the accompanying financial statements;
  - b) In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books, except for the matters stated in paragraph 13 (h)(vi) below on reporting under Rule 11(g) of the Companies (Audit and Auditors) Rules, 2014 (as amended);
  - c) The financial statements dealt with by this report are in agreement with the books of account;
  - d) In our opinion, the aforesaid financial statements comply with Ind AS specified under section 133 of the Act;
  - e) On the basis of the written representations received from the directors and taken on record by the Board of Directors, none of the directors is disqualified as on 31 March 2024 from being appointed as a director in terms of section 164(2) of the Act;
  - f) With respect to the maintenance of accounts and other matters connected therewith refer to our comments in paragraph 13(b) above on reporting under Section 143(3)(b) of the Act and

*e*

# Walker Chandniok & Co LLP

## Independent Auditor's Report on the Audit of the Financial Statements of Jubilant Biosys Limited for the year ended 31 March 2024 (Cont'd)

paragraph 13(h)(vi) below on reporting under rule 11(g) of the of the Companies (Audit and Auditors) Rules, 2014 (as amended);

- g) With respect to the adequacy of the internal financial controls with reference to financial statements of the Company as on 31 March 2024 and the operating effectiveness of such controls, refer to our separate report in Annexure II wherein we have expressed an unmodified opinion; and
- h) With respect to the other matters to be included in the Auditor's Report in accordance with rule 11 of the Companies (Audit and Auditors) Rules, 2014 (as amended), in our opinion and to the best of our information and according to the explanations given to us:
- i. The Company, as detailed in note 35 to the financial statements, has disclosed the impact of pending litigations on its financial position as at 31 March 2024;
  - ii. The Company did not have any long-term contracts including derivative contracts for which there were any material foreseeable losses as at 31 March 2024;
  - iii. There were no amounts which were required to be transferred to the Investor Education and Protection Fund by the Company during the year ended 31 March 2024;
  - iv.
    - a. The management has represented that, to the best of its knowledge and belief, other than as disclosed in note 46(1) to the financial statements, no funds have been advanced or loaned or invested (either from borrowed funds or securities premium or any other sources or kind of funds) by the Company to or in any person(s) or entity(ies), including foreign entities ('the intermediaries'), with the understanding, whether recorded in writing or otherwise, that the intermediary shall, whether, directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Company ('the Ultimate Beneficiaries') or provide any guarantee, security or the like on behalf the Ultimate Beneficiaries;
    - b. The management has represented that, to the best of its knowledge and belief, as disclosed in note 46(2) to the financial statements, no funds have been received by the Company from any person(s) or entity(ies), including foreign entities ('the Funding Parties'), with the understanding, whether recorded in writing or otherwise, that the Company shall, whether directly or indirectly, lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party ('Ultimate Beneficiaries') or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries; and
    - c. Based on such audit procedures performed as considered reasonable and appropriate in the circumstances, nothing has come to our notice that has caused us to believe that the management representations under sub-clauses (a) and (b) above contain any material misstatement.
  - v. The Company has not declared or paid any dividend during the year ended 31 March 2024.
  - vi. As stated in Note 44 to the financial statements and based on our examination which included test checks, the Company, in respect of financial year commencing on 01 April 2023, has used accounting software for maintaining its books of account which has a feature of recording audit trail (edit log) facility and the same have been operated throughout the year for all relevant transactions recorded in the software other than the audit trail feature was not enabled at the database level for accounting software to log any direct data changes for the period 01 April 2023 to 30 November 2023, used for maintenance of all




# Walker Chandiook & Co LLP

Independent Auditor's Report on the Audit of the Financial Statements of Jubilant Biosys Limited for the year ended 31 March 2024 (Cont'd)

accounting and payroll records by the Company. Further, during the course of our audit, we did not come across any instance of audit trail feature being tampered with in respect of the accounting software where such feature is enabled.

For **Walker Chandiook & Co LLP**  
Chartered Accountants  
Firm's Registration No.: 001076N/N500013



**Nitin Toshniwal**  
Partner  
Membership No.: 507568  
UDIN: 24507568BKEJWI2994



**Place:** Noida  
**Date:** 28 May 2024

## Walker Chandiook & Co LLP

### **Annexure I referred to in paragraph 13 of the Independent Auditor's Report of even date to the members of Jubilant Biosys Limited on the financial statements for the year ended 31 March 2024**

In terms of the information and explanations sought by us and given by the Company and the books of account and records examined by us in the normal course of audit, and to the best of our knowledge and belief, we report that:

- (i) (a) (A) The Company has maintained proper records showing full particulars, including quantitative details and situation of property, plant and equipment, capital work-in-progress and relevant details of right-of-use assets.  
  
(B) The Company has maintained proper records showing full particulars of intangible assets.
- (b) The Company has a regular programme of physical verification of its property, plant and equipment under which the assets are physically verified in a phased manner over a period of 3 years, which in our opinion, is reasonable having regard to the size of the Company and the nature of its assets. In accordance with this programme, certain property, plant and equipment were verified during the year and no material discrepancies were noticed on such verification.
- (c) The Company does not own any immovable property (other than properties where the Company is the lessee and the lease agreements are duly executed in favour of the lessee). Accordingly, reporting under clause 3(i)(c) of the Order is not applicable to the Company.
- (d) The Company has not revalued its property, plant and equipment including right-of-use assets or intangible assets during the year.
- (e) No proceedings have been initiated or are pending against the Company for holding any benami property under the Prohibition of Benami Property Transactions Act, 1988 (as amended) and rules made thereunder.
- (ii) (a) The management has conducted physical verification of inventory at reasonable intervals during the year. In our opinion, the coverage and procedure of such verification by the management is appropriate and no discrepancies of 10% or more in the aggregate for each class of inventory were noticed as compared to book records.  
  
(b) As disclosed in Note 15 to the financial statements, the Company has been sanctioned a working capital limit in excess of INR 5 crores by banks based on the security of current assets. The quarterly statements, in respect of the working capital limits have been filed by the Company with such banks and such statements are in agreement with the books of account of the Company for the respective periods, which were subject to review.
- (iii) The Company has not provided any guarantee or security or granted advances in the nature of loans to companies, firms, limited liability partnerships during the year. Further, the Company has made investment in company, granted an unsecured loan to a company (subsidiary) including other parties (employees) during the year, in respect of which:



## Walker ChandioK & Co LLP

Annexure I referred to in Paragraph 13 of the Independent Auditor's Report of even date to the members of Jubilant Biosys Limited on the financial statements for the year ended 31 March 2024 (cont'd)

- a) The Company has provided loans to Subsidiaries and Others during the year as per details given below:

	Loans (INR in lakhs)
Aggregate amount granted during the year:	
Subsidiaries	2,491.35
Others	191.45
Balance outstanding as at balance sheet date in respect of above cases:	
Subsidiaries	2,502.15
Others	62.21

- b) In our opinion, and according to the information and explanations given to us, the investments made and terms and conditions of the grant of all loans provided are, prima facie, not prejudicial to the interest of the Company.
- c) In respect of loans granted by the Company, the schedule of repayment of principal and payment of interest has been stipulated and the repayments or receipts of principal and interest are regular.
- d) There is no amount which is overdue for more than 90 days in respect of loans granted to other parties (employees).
- e) The Company has not granted any loan which has fallen due during the year. Further, no fresh loans were granted to any party to settle the overdue loans in nature of loan that existed as at the beginning of the year.
- f) The Company has not granted any loans, which are repayable on demand or without specifying any terms or period of repayment.
- (iv) In our opinion, and according to the information and explanations given to us, the Company has complied with the provisions of section 186 of the Act in respect of investments made and loans granted. Further, the Company has not entered into any transaction covered under section 185 and section 186 of the Act in respect of guarantees and security provided by it.
- (v) In our opinion, and according to the information and explanations given to us, the Company has not accepted any deposits or there are no amounts which have been deemed to be deposits within the meaning of sections 73 to 76 of the Act and the Companies (Acceptance of Deposits) Rules, 2014 (as amended). Accordingly, reporting under clause 3(v) of the Order is not applicable to the Company.
- (vi) The Central Government has not specified maintenance of cost records under sub-section (1) of section 148 of the Act, in respect of Company's products/ services / business activities. Accordingly, reporting under clause 3(vi) of the Order is not applicable.
- (vii)(a) In our opinion, and according to the information and explanations given to us, the Company is generally regular in depositing undisputed statutory dues including goods and services tax, provident fund, employees' state insurance, income-tax, sales-tax, service tax, duty of customs, duty of excise, value added tax, cess and other material statutory dues, as applicable, with the appropriate authorities. Further, no undisputed



## Walker Chandiook & Co LLP

Annexure I referred to in Paragraph 13 of the Independent Auditor's Report of even date to the members of Jubilant Biosys Limited on the financial statements for the year ended 31 March 2024 (cont'd)

amounts payable in respect thereof were outstanding at the year-end for a period of more than six months from the date they became payable.

- (b) According to the information and explanations given to us, there are no statutory dues referred in sub-clause (a) which have not been deposited with the appropriate authorities on account of any dispute except for the following:

Name of the statute	Nature of dues	Gross Amount (INR In lakhs*)	Amount paid Under Protest (INR in lakhs)	Period to which the amount relates (FY)	Forum where dispute is pending
Goods and services Act, 2017	Goods and services tax	2.11	0.24	July 2017-March 2018	Goods and Services Tax Tribunal
Finance Act, 1994	Service tax	17.13	2.57	January 2016 - June 2017	CESTAT, Bangalore
Income Tax Act, 1961	Income tax	3,781.66	NIL	2010-11	Allahabad High Court
Income Tax Act, 1961	Income tax	5,932.80	NIL	2011-12	Allahabad High Court
Income Tax Act, 1961	Income tax	8,219.92	NIL	2012-13	Allahabad High Court
Income Tax Act, 1961	Income tax	4,182.28	NIL	2012-13	Allahabad High Court
Income Tax Act, 1961	Income tax	7,690.86	NIL	2013-14	Allahabad High Court
Income Tax Act, 1961	Income tax	212.57	NIL	2013-14	Commissioner of Income Tax (Appeals)
Income Tax Ac, 1961	Income tax	127.67	NIL	2017-18	Commissioner of Income Tax (Appeals)
Income Tax Ac, 1961	Income tax	86.13	NIL	2017-18	ITAT, Delhi
Income Tax Ac, 1961	Income tax	335.42	NIL	2020-21	Commissioner of Income Tax (Appeals)

\*inclusive of interest and penalties





## Walker Chandiook & Co LLP

Annexure I referred to in Paragraph 13 of the Independent Auditor's Report of even date to the members of Jubilant Biosys Limited on the financial statements for the year ended 31 March 2024 (cont'd)

- (viii) According to the information and explanations given to us, no transactions were surrendered or disclosed as income during the year in the tax assessments under the Income Tax Act, 1961 (43 of 1961) which have not been previously recorded in the books of accounts.
- (ix) (a) According to the information and explanations given to us, the Company has not defaulted in repayment of its loans or borrowings or in the payment of interest thereon to any lender.
- (b) According to the information and explanations given to us including confirmations received from banks and financial institution representation received from the management of the Company, and on the basis of our audit procedures, we report that the Company has not been declared a willful defaulter by any bank or financial institution or government or any government authority.
- (c) In our opinion and according to the information and explanations given to us, money raised by way of term loans were applied for the purposes for which these were obtained.
- (d) In our opinion and according to the information and explanations given to us, and on an overall examination of the financial statements of the Company, funds raised by the Company on short term basis have, prima facie, not been utilised for long term purposes.
- (e) According to the information and explanations given to us and on an overall examination of the financial statements of the Company, the Company has not taken any funds from any entity or person on account of or to meet the obligations of its subsidiaries.
- (f) According to the information and explanations given to us, the Company has not raised any loans during the year on the pledge of securities held in its subsidiaries .
- (x) (a) The Company has not raised any money by way of initial public offer or further public offer (including debt instruments), during the year. Accordingly, reporting under clause 3(x)(a) of the Order is not applicable to the Company.
- (b) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has not made any preferential allotment or private placement of shares or (fully, partially or optionally) convertible debentures during the year. Accordingly, reporting under clause 3(x)(b) of the Order is not applicable to the Company.
- (xi) (a) To the best of our knowledge and according to the information and explanations given to us, no fraud by the Company or no fraud on the Company has been noticed or reported during the period covered by our audit.
- (b) According to the information and explanations given to us including the representation made to us by the management of the Company, no report under sub-section 12 of section 143 of the Act has been filed by the auditors in Form ADT-4 as prescribed under rule 13 of Companies (Audit and Auditors) Rules, 2014, with the Central Government for the period covered by our audit.



## Walker Chandiook & Co LLP

### Annexure I referred to in Paragraph 13 of the Independent Auditor's Report of even date to the members of Jubilant Biosys Limited on the financial statements for the year ended 31 March 2024 (cont'd)

- (c) According to the information and explanations given to us including the representation made to us by the management of the Company, there are no whistle-blower complaints received by the Company during the year.
- (xii) The Company is not a Nidhi Company and the Nidhi Rules, 2014 are not applicable to it. Accordingly, reporting under clause 3(xii) of the Order is not applicable to the Company.
- (xiii) In our opinion and according to the information and explanations given to us, all transactions entered into by the Company, with the related parties are in compliance with section 188 of the Act. The details of such related party transactions have been disclosed in the standalone financial statements etc., as required under Indian Accounting Standard (Ind AS) 24, Related Party Disclosures specified in Companies (Indian Accounting Standards) Rules 2015 as prescribed under section 133 of the Act. Further, according to the information and explanations given to us, the Company is not required to constitute an audit committee under section 177 of the Act.
- (xiv) (a) In our opinion and according to the information and explanations given to us, the Company has an internal audit system which is commensurate with the size and nature of its business as required under the provisions of section 138 of the Act.  
  
(b) We have considered the reports issued by the Internal Auditors of the Company till date for the period under audit.
- (xv) According to the information and explanation given to us, the Company has not entered into any non-cash transactions with its directors or persons connected with its directors and accordingly, reporting under clause 3(xv) of the Order with respect to compliance with the provisions of section 192 of the Act are not applicable to the Company.
- (xvi) The Company is not required to be registered under section 45-IA of the Reserve Bank of India Act, 1934. Accordingly, reporting under clauses 3(xvi)(a), (b) and (c) of the Order are not applicable to the Company.  
  
(d) Based on the information and explanations given to us and as represented by the management of the Company, the Group (as defined in Core Investment Companies (Reserve Bank) Directions, 2016) does not have any CIC.
- (xvii) The Company has not incurred any cash losses in the current financial year as well as the immediately preceding financial year.
- (xviii) There has been no resignation of the statutory auditors during the year. Accordingly, reporting under clause 3(xviii) of the Order is not applicable to the Company.
- (xix) According to the information and explanations given to us and on the basis of the financial ratios, ageing and expected dates of realisation of financial assets and payment of financial liabilities, other information in the financial statements, our knowledge of the plans of the Board of Directors and management and based on our examination of the evidence supporting the assumptions, nothing has come to our attention, which causes us to believe that any material uncertainty exists as on the date of the audit report indicating that Company is not capable of meeting its liabilities existing at the date of balance sheet as and when they fall due within a period of one year from the balance sheet date. We, however, state that this is not an assurance as to the future viability of the company. We further state that our reporting is based on the facts up to the date of the audit report and we neither give any guarantee nor any assurance that all liabilities falling due within a period of one year from the balance sheet date, will get discharged by the company as and when they fall due.




## Walker Chandiook & Co LLP

Annexure I referred to in Paragraph 13 of the Independent Auditor's Report of even date to the members of Jubilant Biosys Limited on the financial statements for the year ended 31 March 2024 (cont'd)

- (xx) According to the information and explanations given to us, the Company does not have any unspent amounts towards Corporate Social Responsibility in respect of any ongoing or other than ongoing project as at the end of the financial year. Accordingly, reporting under clause 3(xx) of the Order is not applicable to the Company.
- (xxi) The reporting under clause 3(xxi) of the Order is not applicable in respect of audit of financial statements of the Company. Accordingly, no comment has been included in respect of said clause under this report.

For **Walker Chandiook & Co LLP**  
Chartered Accountants  
Firm's Registration No.: 001076N/N500013



**Nitin Toshniwal**  
Partner  
Membership No.: 507568  
UDIN: 24507568BKEJWI2994



**Place:** Noida  
**Date:** 28 May 2024

## Annexure II

### **Independent Auditor's Report on the internal financial controls with reference to the financial statements of Jubilant Biosys Limited under Clause (i) of Sub-section 3 of Section 143 of the Companies Act, 2013 ('the Act')**

1. In conjunction with our audit of the financial statements of Jubilant Biosys Limited ('the Company') as at and for the year ended 31 March 2024, we have audited the internal financial controls with reference to financial statements of the Company as at that date.

### **Responsibilities of Management and Those Charged with Governance for Internal Financial Controls**

2. The Company's Board of Directors is responsible for establishing and maintaining internal financial controls based on the internal financial controls with reference to financial statements criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls over Financial Reporting ('the Guidance Note') issued by the ICAI. These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of the Company's business, including adherence to the Company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Act.

### **Auditor's Responsibility for the Audit of the Internal Financial Controls with Reference to Financial Statements**

3. Our responsibility is to express an opinion on the Company's internal financial controls with reference to financial statements based on our audit. We conducted our audit in accordance with the Standards on Auditing issued by ICAI prescribed under Section 143(10) of the Act, to the extent applicable to an audit of internal financial controls with reference to financial statements, and the Guidance Note issued by the ICAI. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls with reference to financial statements were established and maintained and if such controls operated effectively in all material respects.
4. Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls with reference to financial statements and their operating effectiveness. Our audit of internal financial controls with reference to financial statements includes obtaining an understanding of such internal financial controls, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor's judgement, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error.
5. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Company's internal financial controls with reference to financial statements

### **Meaning of Internal Financial Controls with Reference to Financial Statements**

6. A company's internal financial controls with reference to financial statements is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal financial controls with reference to financial statements include those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide



## Walker ChandioK & Co LLP

### Annexure II to the Independent Auditor's Report of even date to the members of Jubilant Biosys Limited on the financial statements for the year ended 31 March 2024 (cont'd)

reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorisations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorised acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.


#### Inherent Limitations of Internal Financial Controls with Reference to Financial Statements

7. Because of the inherent limitations of internal financial controls with reference to financial statements, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls with reference to financial statements to future periods are subject to the risk that the internal financial controls with reference to financial statements may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

#### Opinion

8. In our opinion, the Company has, in all material respects, adequate internal financial controls with reference to financial statements and such controls were operating effectively as at 31 March 2024, based on the internal financial controls with reference to financial statements criteria established by the Company considering the essential components of internal control stated in the Guidance Note issued by the ICAI.

For **Walker ChandioK & Co LLP**  
Chartered Accountants  
Firm's Registration No.: 001076N/N500013



**Nitin Toshniwal**  
Partner  
Membership No.: 507568  
UDIN: 24507568BKEJWI2994

**Place:** Noida  
**Date:** 28 May 2024




Jubilant Biosys Limited  
Balance Sheet as at 31 March 2024  
(All amounts are in INR lakhs unless otherwise stated)

	Notes	As at 31 March 2024	As at 31 March 2023
<b>ASSETS</b>			
<b>Non-current assets</b>			
Property, plant and equipment	3	37,313.25	25,644.76
Capital work-in-progress	3	945.96	10,137.48
Other intangible assets	4	341.56	335.80
Right of use assets	37	6,080.47	6,012.48
<b>Financial assets</b>			
i. Investments	5	4,683.93	4,679.22
ii. Loans	6	10,402.15	16,117.00
iii. Other financial assets	7	431.63	366.37
Deferred tax assets (net)	8	362.51	287.62
Income tax asset (net)		430.67	444.57
Other non-current assets	9	228.96	332.47
<b>Total non-current assets</b>		<b>61,221.09</b>	<b>64,357.77</b>
<b>Current assets</b>			
Inventories	10	1,231.72	187.26
<b>Financial assets</b>			
i. Trade receivables	11	8,326.71	10,062.45
ii. Cash and cash equivalents	12(a)	3,161.79	465.25
iii. Other bank balances	12(b)	0.36	0.36
iv. Loans	6	62.21	66.80
v. Other financial assets	7	1,433.54	1,306.64
Other current assets	13	4,420.15	5,301.63
<b>Total current assets</b>		<b>18,636.48</b>	<b>17,390.39</b>
<b>Total assets</b>		<b>79,857.57</b>	<b>81,748.16</b>
<b>EQUITY AND LIABILITIES</b>			
<b>Equity</b>			
Equity share capital	14	25,214.05	25,214.05
Other equity	14	28,081.13	25,252.48
<b>Total equity</b>		<b>53,295.18</b>	<b>50,466.53</b>
<b>LIABILITIES</b>			
<b>Non-current liabilities</b>			
<b>Financial Liabilities</b>			
i. Borrowings	15	10,968.73	15,121.91
ii. Lease Liabilities	37	2,761.77	3,020.33
Provisions	16	1,612.91	1,450.84
<b>Total non-current liabilities</b>		<b>15,343.41</b>	<b>19,593.08</b>
<b>Current liabilities</b>			
<b>Financial liabilities</b>			
i. Short-term borrowings	15A	2,448.19	3,725.00
ii. Lease Liabilities	37	1,118.39	819.84
iii. Trade payables	17		
Total outstanding dues to micro enterprises and small enterprises		418.69	400.96
Total outstanding dues to creditors other than micro enterprises and small enterprises		2,168.35	2,460.42
iv. Other financial liabilities	18	2,659.91	2,931.41
Other current liabilities	19	1,903.33	758.29
Provisions	16	239.66	217.88
Current tax liabilities (net)		262.46	374.75
<b>Total current liabilities</b>		<b>11,218.98</b>	<b>11,688.55</b>
<b>Total liabilities</b>		<b>26,562.39</b>	<b>31,281.63</b>
<b>Total equity and liabilities</b>		<b>79,857.57</b>	<b>81,748.16</b>

The accompanying notes form an integral part of the financial statements  
As per our report of even date attached

For Walker Chandio & Co LLP  
Chartered Accountants  
Firm registration number: 001076N/N500013


  
Nitin Toshniwal  
Partner

Membership No: 507568  
Place: Noida  
Date: 28 May 2024




For and on behalf of Board of Directors of  
Jubilant Biosys Limited

  
Giuliano Perfetti  
Chief Executive Officer and  
Managing Director  
DIN: 09357368  
Place: Noida  
Date: 28 May 2024

  
Irfan Ali  
Company Secretary  
Place: Noida  
Date: 28 May 2024

  
Prasant Kumar Deb  
Whole Time Director  
DIN: 09187850  
Place: Noida  
Date: 28 May 2024


  
Benny Thomas  
Chief Financial Officer  
Place: Bengaluru  
Date: 28 May 2024

**Jubilant Biosys Limited**  
**Statement of Profit and Loss for the year ended 31 March 2024**  
(All amounts are in INR lakhs unless otherwise stated)

	Notes	Year ended 31 March 2024	Year ended 31 March 2023
Revenue from operations	20	45,192.28	54,514.79
Other income	21	1,952.24	1,771.69
<b>Total income</b>		<b>47,144.52</b>	<b>56,286.48</b>
<b>Expenses</b>			
Cost of material consumed	22	399.12	1,072.27
Changes in inventories of work-in-progress and finished goods	23	(1,059.79)	417.76
Employee benefits expense	24	14,542.54	14,313.28
Finance costs	25	1,473.75	1,210.24
Depreciation and amortisation expense	26	5,159.39	3,278.41
Other expenses	27	22,716.91	23,410.03
<b>Total expenses</b>		<b>43,231.92</b>	<b>43,701.99</b>
<b>Profit before tax</b>		<b>3,912.60</b>	<b>12,584.49</b>
Tax expense	28		
- Current tax		1,125.86	3,063.61
- Deferred tax expense/ (credit)		(66.59)	181.06
<b>Total tax expense</b>		<b>1,059.27</b>	<b>3,244.67</b>
<b>Profit for the year</b>		<b>2,853.33</b>	<b>9,339.82</b>
<b>Other comprehensive income</b>			
Items that will not be reclassified to profit or loss			
Re-measurement of defined benefit obligations		(32.98)	(71.19)
Income tax relating to these items		8.30	17.92
Other comprehensive loss for the year, net of tax		(24.68)	(53.27)
<b>Total comprehensive income for the year</b>		<b>2,828.65</b>	<b>9,286.55</b>
<b>Earnings per equity share of INR 10 each</b>			
Basic earnings per share	38	1.13	3.70
Diluted earnings per share		1.13	3.70

The accompanying notes form an integral part of the financial statements  
As per our report of even date attached

**For Walker Chandioik & Co LLP**  
Chartered Accountants  
Firm registration number: 001076N/N500013



**Nifin Toshniwal**  
Partner

Membership No: 507568  
Place: Noida  
Date: 28 May 2024



**For and on behalf of Board of Directors of  
Jubilant Biosys Limited**



**Giuliano Perletti**  
Chief Executive Officer and  
Managing Director

DIN: 09357368  
Place: Noida  
Date: 28 May 2024



**Prasant Kumar Deb**  
Whole Time Director

DIN: 09187850  
Place: Noida  
Date: 28 May 2024



**Irfan Ali**  
Company Secretary  
Place: Noida  
Date: 28 May 2024



**Benny Thomas**  
Chief Financial Officer  
Place: Bengaluru  
Date: 28 May 2024

Jubilant Biosys Limited  
Statement of cash flows for the year ended 31 March 2024  
(All amounts are in INR lakhs unless otherwise stated)

	Year ended 31 March 2024	Year ended 31 March 2023
<b>A. Cash flows from operating activities</b>		
Net profit before tax	3,912.60	12,584.49
Adjustments :		
Depreciation and amortisation expense	5,159.39	3,278.41
Loss on sale/ write off of property, plant and equipment (net)	49.57	66.42
Finance costs	1,473.75	1,210.24
Allowance/ expected credit allowance	637.93	-
Written off balance	1.76	1.10
Liabilities written back	(0.43)	(2.09)
Unrealised foreign exchange (gain)/ loss	(71.76)	(25.59)
Interest income	(930.00)	(622.86)
Cash flows from operating activities before working capital changes	10,232.81	16,490.12
Decrease/(increase) in trade receivables, other financial assets and other assets	1,888.81	(4,299.90)
(Increase)/decrease in inventories	(1,044.46)	437.47
Increase/(decrease) in trade payables, provisions and other liabilities	1,505.65	(248.61)
Cash generated from operations	12,582.81	12,379.08
Income tax paid (net of refund)	(1,224.25)	(3,151.26)
Net cash generated from operating activities (A)	11,358.56	9,227.82
<b>B. Cash flow from investing activities</b>		
Purchase of property, plant and equipment, other intangible assets including capital work-in-progress	(6,881.33)	(13,024.78)
Proceeds from sale of property, plant and equipment	10.84	47.15
Movement in other bank balances	-	1.00
Interest received	857.91	614.97
Purchase of investment in subsidiary	-	(402.16)
Purchase of investment in others	(64.66)	-
Realised forex (loss) on the repayment of loans advanced	(30.86)	-
Loans granted to related party	(2,491.35)	(8,250.00)
Repayment of loans advanced from related party	8,250.00	-
Net cash used in investing activities (B)	(349.45)	(21,013.82)
<b>C. Cash flow arising from financing activities*</b>		
Proceeds from long term borrowings	1,720.27	9,965.66
Repayment of short term borrowings	(1,850.00)	1,850.00
Principal payments under long term borrowings	(5,300.26)	(468.75)
Principal lease payments	(1,150.11)	(888.65)
Finance costs paid (including finance cost on lease obligations)	(1,732.47)	(914.44)
Net cash arising from financing activities (C)	(8,312.57)	9,543.82
Net (decrease)/increase in cash and cash equivalents (A+B+C)	2,696.54	(2,242.18)
Add: cash and cash equivalents at the beginning of year	465.25	2,707.43
Cash and cash equivalents at the end of the year (Refer Note 12(a))	3,161.79	465.25

\*Refer note 15 for changes in liabilities arising from financing activities

Note: Statement of Cash flow has been prepared under the indirect method as set out in the Ind AS 7-"Statement of Cash flows".


The accompanying notes form an integral part of the financial statements

As per our report of even date attached

For Walker Chandniok & Co LLP

Chartered Accountants

Firm registration number: 001076N/N500013

  
Nisha Toshniwal  
Partner

Membership No: 507568

Place: Noida

Date: 28 May 2024




For and on behalf of Board of Directors of  
Jubilant Biosys Limited

  
Giuliano Perfetti  
Chief Executive Officer and  
Managing Director

DIN: 09357368

Place: Noida

Date: 28 May 2024



Irfan Ali  
Company Secretary

Place: Noida


Date: 28 May 2024

  
Prasant Kumar Deb  
Whole Time Director

DIN: 09187850

Place: Noida

Date: 28 May 2024



Benny Thomas  
Chief Financial Officer

Place: Bengaluru

Date: 28 May 2024



Jubilant Biosys Limited  
Statement of changes in Equity for the year ended 31 March 2024  
(All amounts are in INR lakhs unless otherwise stated)


a) Equity share capital	Note	Amount
Balance as at 1 April 2022	14	25,214.05
Equity shares issued during the year		-
<b>Balance as at 31 March 2023</b>	14	<b>25,214.05</b>
Equity shares issued during the year		-
<b>Balance as at 31 March 2024</b>	14	<b>25,214.05</b>

b) Other Equity	Reserves and surplus					Total
	Capital reserve	Amalgamation adjustment deficit account	Securities premium	Capital redemption reserve	Retained earnings	
Balance as at 1 April 2022	2,637.36	(6,162.22)	1,922.71	3,885.00	13,683.08	15,965.93
Profit for the year	-	-	-	-	9,339.82	9,339.82
Other comprehensive loss	-	-	-	-	(53.27)	(53.27)
<b>Balance as at 31 March 2023</b>	<b>2,637.36</b>	<b>(6,162.22)</b>	<b>1,922.71</b>	<b>3,885.00</b>	<b>22,969.63</b>	<b>25,252.48</b>
Profit for the year	-	-	-	-	2,853.33	2,853.33
Other comprehensive loss	-	-	-	-	(24.68)	(24.68)
<b>Balance as at 31 March 2024</b>	<b>2,637.36</b>	<b>(6,162.22)</b>	<b>1,922.71</b>	<b>3,885.00</b>	<b>25,798.28</b>	<b>28,081.13</b>

Refer note 14 (2) for nature and purpose of equity.  
The accompanying notes form an integral part of the financial statements.  
As per our report of even date attached

For Walker Chandiook & Co LLP  
Chartered Accountants  
Firm registration number: 001076N/N500013



Nitin Toshniwal  
Partner  
Membership No: 507568  
Place: Noida  
Date: 28 May 2024




For and on behalf of Board of Directors of Jubilant Biosys Limited



Giuliano Perfetti  
Chief Executive Officer and Managing Director  
DIN: 09357368  
Place: Noida  
Date: 28 May 2024



Irfan Ali  
Company Secretary  
Place: Noida  
Date: 28 May 2024



Prasant Kumar Deb  
Whole Time Director  
DIN: 09187850  
Place: Noida  
Date: 28 May 2024



Benny Thomas  
Chief Financial Officer  
Place: Bengaluru  
Date: 28 May 2024



**Jubilant Biosys Limited**

Notes to the financial statements for the year ended 31 March 2024

(All amounts are in INR lakhs unless otherwise stated)

## (iii) Depreciation and amortization methods, estimated useful lives and residual value

Depreciation is provided on straight line basis on the original cost/ acquisition cost of assets or other amounts substituted for cost of fixed assets as per the useful life specified in Part 'C' of Schedule II of the Act, read with notification dated 29 August 2014 of the Ministry of Corporate Affairs, except for the following classes of fixed assets which are depreciated based on the internal technical assessment of the management as under:

Category of assets	Management estimate of useful life	Useful life as per Schedule II
Computer servers and networks (included in office equipment)	5 years	6 years
Leasehold improvement	Useful life as defined by management	Useful life or leased period whichever is less

Leasehold land which qualifies as finance lease is amortised over the lease period on straight line basis.

Software systems are being amortised over a period of five years being their useful life.

Depreciation and amortization on property, plant and equipment and intangible assets added/disposed off during the year has been provided on pro-rata basis with reference to the date of addition/disposal. Depreciation and amortization methods, useful lives and residual values are reviewed at the end of each reporting period and adjusted if appropriate.

## (iv) Derecognition

A property, plant and equipment and intangible assets is derecognised on disposal or when no future economic benefits are expected from its use and disposal. Losses arising from retirement and gains or losses arising from disposal of a tangible asset are measured as the difference between the net disposal proceeds and the carrying amount of the asset and are recognised in the Statement of Profit and Loss.

**(d) Impairment of non-financial assets**

The Company's non-financial assets other than inventories and deferred tax assets, are reviewed at each reporting date to determine whether there is any indication of impairment. If any such indication exists, then the asset's recoverable amount is estimated.

For impairment testing, assets that do not generate independent cash inflows are grouped together into cash-generating units (CGUs). Each CGU represents the smallest group of assets that generates cash inflows that are largely independent of the cash inflows of other assets or CGUs.

The recoverable amount of a CGU is the higher of its value in use and its fair value less costs to sell. Value in use is based on the estimated future cash flows, discounted to their present value using a discount rate that reflects current market assessments of the time value of money and the risks specific to the CGU.

An impairment loss is recognised if the carrying amount of an asset or CGU exceeds its estimated recoverable amount. Impairment loss recognized in respect of a CGU is allocated first to reduce the carrying amounts of the other assets of the CGU (or group of CGUs) on a pro rata basis.

An impairment loss in respect of assets for which impairment loss has been recognized in prior periods, the Company reviews at reporting date whether there is any indication that the loss has decreased or no longer exists. An impairment loss is reversed if there has been a change in the estimates used to determine the recoverable amount. Such a reversal is made only to the extent that the asset's carrying amount does not exceed the carrying amount that would have been determined, net of depreciation or amortization, if no impairment loss had been recognized.

**(e) Financial instrument**

A financial instrument is any contract that gives rise to a financial asset of one entity and a financial liability or equity instrument of another entity.

## (i) Financial assets

*Initial recognition and measurement*

All financial assets are recognised initially at fair value plus, in the case of financial assets not recorded at fair value through profit or loss, transaction costs that are attributable to the acquisition of the financial asset. Purchases or sales of financial assets that require delivery of assets within a time frame established by regulation or convention in the market place (regular way trades) are recognised on the trade date, i.e., the date that the Company commits to purchase or sell the asset

*Subsequent measurement*

For purposes of subsequent measurement, financial assets are classified in four categories:

- i. Debt instruments at amortized cost
- ii. Debt instruments at fair value through other comprehensive income (FVOCI)
- iii. Debt instruments, derivatives and equity instruments at fair value through profit or loss (FVTPL)
- iv. Equity instruments measured at fair value through other comprehensive income (FVOCI)

*Debt instruments at amortised cost*

A 'debt instrument' is measured at the amortised cost if both the following conditions are met:

- i. The asset is held within a business model whose objective is to hold assets for collecting contractual cash flows, and
- ii. Contractual terms of the asset give rise to cash flows that are solely payments of principal and interest (SPPI) on the principal amount outstanding.



## Jubilant Biosys Limited

Notes to the financial statements for the year ended 31 March 2024

(All amounts are in INR lakhs unless otherwise stated)

After initial measurement, such financial assets are subsequently measured at amortised cost using the effective interest rate (EIR) method. Amortised cost is calculated by taking into account any discount or premium on acquisition and fees or costs that are an integral part of the EIR. The EIR amortisation is included in other income in the Statement of Profit and Loss. The losses arising from impairment are recognised in the Statement of Profit and Loss. This category generally applies to trade and other receivables.

### *Debt instrument at FVOCI*

A 'debt instrument' is classified as at the FVOCI if both of the following criteria are met:

- i. The objective of the business model is achieved both by collecting contractual cash flows and selling the financial assets, and
- ii. The asset's contractual cash flows represent SPPI.

Debt instruments included within the FVOCI category are measured initially as well as at each reporting date at fair value. Fair value movements are recognised in the other comprehensive income (OCI). On derecognition of the asset, cumulative gain or loss previously recognised in OCI is reclassified to the Statement of Profit and Loss. Interest earned whilst holding FVOCI debt instrument is reported as interest income using the EIR method.

### *Debt instrument at FVTPL*

FVTPL is a residual category for debt instruments. Any debt instrument, which does not meet the criteria for categorisation as at amortised cost or as FVOCI, is classified as at FVTPL.

In addition, the Company may elect to designate a debt instrument, which otherwise meets amortised cost or FVOCI criteria, as at FVTPL. However, such election is allowed only if doing so reduces or eliminates a measurement or recognition inconsistency (referred to as 'accounting mismatch').

Debt instruments included within the FVPL category are measured at fair value with all changes recognised in the Statement of Profit and Loss.

### *Equity investments*

All equity investments in scope of Ind AS 109 are measured at fair value. Equity instruments which are held for trading and contingent consideration recognised by an acquirer in a business combination to which Ind AS 103 applies are classified as at FVPL. For all other equity instruments, the Company may make an irrevocable election to present in other comprehensive income subsequent changes in the fair value. The Company makes such election on an instrument by-instrument basis. The classification is made on initial recognition and is irrevocable.

If the Company decides to classify an equity instrument as at FVOCI, then all fair value changes on the instrument, excluding dividends, are recognised in the OCI. There is no recycling of the amounts from OCI to the Statement of Profit and Loss, even on sale of investment. However, the Company may transfer the cumulative gain or loss within equity.

Equity instruments included within the FVTPL category are measured at fair value with all changes recognised in the Statement of Profit and Loss.

### *Investments in subsidiaries*

Investments in subsidiaries are carried at cost less accumulated impairment losses, if any. Where an indication of impairment exists, the carrying amount of the investment is assessed and written down immediately to its recoverable amount. On disposal of investments in subsidiaries, the difference between net disposal proceeds and the carrying amounts are recognised in the Statement of Profit and Loss.

### *Impairment of financial assets*

The Company recognizes loss allowance using the expected credit loss (ECL) model for the financial assets which are not fair valued through profit or loss. Loss allowance for trade receivables with no significant financing component is measured at an amount equal to lifetime ECL. For all financial assets with contractual cash flows other than trade receivable, ECLs are measured at an amount equal to the 12-month ECL, unless there has been a significant increase in credit risk from initial recognition in which case those are measured at lifetime ECL. The amount of ECLs (or reversal) that is required to adjust the loss allowance at the reporting date to the amount is required to be recognised as an impairment gain or loss in the Statement of Profit and Loss.

### *Derecognition of financial assets*

A financial asset (or, where applicable, a part of a financial asset or part of a group of similar financial assets) is primarily derecognized (i.e., removed from the Company's balance sheet) when:

- i. The rights to receive cash flows from the asset have expired, or
- ii. The Company has transferred its rights to receive cash flows from the asset or has assumed an obligation to pay the received cash flows in full without material delay to a third party under a 'pass-through' arrangement; and either (a) the Company has transferred substantially all the risks and rewards of the asset, or (b) the Company has neither transferred nor retained substantially all the risks and rewards of the asset, but has transferred control of the asset.

When the Company has transferred its rights to receive cash flows from an asset or has entered into a pass-through arrangement, it evaluates if and to what extent it has retained the risks and rewards of ownership. When it has neither transferred nor retained substantially all of the risks and rewards of the asset, nor transferred control of the asset, the Company continues to recognise the transferred asset to the extent of the Company's continuing involvement. In that case, the Company also recognises an associated liability. The transferred asset and the associated liability are measured on a basis that reflects the rights and obligations that the Company has retained.



**Jubilant Biosys Limited**

**Notes to the financial statements for the year ended 31 March 2024**

**(All amounts are in INR lakhs unless otherwise stated)**

*Financial liabilities*

Financial liabilities are classified as measured at amortised cost or FVTPL. A financial liability is classified as at FVTPL if it is classified as held-for-trading, or it is a derivative or it is designated as such on initial recognition. Financial liabilities at FVTPL are measured at fair value and net gains and losses, including any interest expense, are recognised in Statement of Profit and Loss. Other financial liabilities are subsequently measured at amortised cost using the effective interest method. Interest expense and foreign exchange gains and losses are recognised in Statement of Profit and Loss. Any gain or loss on derecognition is also recognised in Statement of Profit and Loss.

*Derecognition of financial liabilities*

A financial liability is derecognised when the obligation under the liability is discharged or cancelled or expires. When an existing financial liability is replaced by another from the same lender on substantially different terms, or the terms of an existing liability are substantially modified, such an exchange or modification is treated as the derecognition of the original liability and the recognition of a new liability. The difference in the respective carrying amounts is recognised in the Statement of Profit and Loss.

*Offsetting*

Financial assets and financial liabilities are offset and the net amount presented in the Balance Sheet when, and only when, the Company currently has a legally enforceable right to set off the amounts and it intends either to settle them on a net basis or to realise the asset and settle the liability simultaneously.

**(f) Inventories**

Inventories are valued at lower of cost or net realisable value except scrap, which is valued at net estimated realisable value. The Company uses weighted average method to determine cost of lab chemical and consumables. Cost includes all costs of purchase, costs of conversion and other costs incurred in bringing the inventories to their present location and condition inclusive of non-refundable (adjustable) taxes wherever applicable.

Net realisable value is the estimated selling price in the ordinary course of business, less the estimated costs of completion and the estimated costs necessary to make the sale. The net realisable value of work-in-progress is determined with reference to the selling prices of related finished products. Raw materials and other supplies held for use in the production of finished products are not written down below cost, except in cases where material prices have declined and it is estimated that the cost of the finished products will exceed their net realisable value. The comparison of cost and net realisable value is made on an item-by-item basis.

**(g) Cash and cash equivalents**

Cash and cash equivalent comprise cash at banks and on hand (including imprest) and short-term deposits with an original maturity of three months or less, which are subject to an insignificant risk of changes in value.

**(h) Provisions and contingencies**

A provision is recognized if, as a result of a past event, the Company has a present legal or constructive obligation that can be estimated reliably, and it is probable that an outflow of economic benefits will be required to settle the obligation. If the effect of the time value of money is material, provisions are determined by discounting the expected future cash flows at a pre-tax rate that reflects current market assessments of the time value of money and the risks specific to the liability. Where discounting is used, the increase in the provision due to the passage of time is recognized as a finance cost.

The amount recognized as a provision is the best estimate of the consideration required to settle the present obligation at reporting date, taking into account the risks and uncertainties surrounding the obligation. When some or all of the economic benefits required to settle a provision are expected to be recovered from a third party, the receivable is recognized as an asset if it is virtually certain that reimbursement will be received and the amount of the receivable can be measured reliably.

*Contingent liability*

A disclosure for a contingent liability is made when there is a possible obligation or a present obligation that may, but probably will not, require an outflow of resources. When there is a possible obligation or a present obligation in respect of which the likelihood of outflow of resources is remote, no provision or disclosure is made.

**(i) Revenue recognition**

Service income is recognised as and when the underlying services are performed. Revenue from projects taken up as per the specification of the customer is recognised on the approval of / delivery to the customer.

Revenues are measured based on the transaction price, which is the consideration, net of tax collected from customers and remitted to government authorities such as Goods and services tax (GST) and applicable discounts and allowances.

Contract assets are recognised when there is excess of revenue earned over billings on contracts. Contract assets are classified as unbilled receivables (only act of invoicing is pending) when there is unconditional right to receive cash, and only passage of time is required, as per contractual terms. Contract liabilities are recognised when there are billings in excess of revenues. Contract liabilities relate to the advance received from customers and deferred revenue against which revenue is recognised when or as the performance obligation is satisfied.

Revenue from projects taken up as per the specification of the customers is recognized on the shipment of compounds to the customer.

**(j) Employee benefits**

**(i) Short-term employee benefits:**

All employee benefits falling due within twelve months of the end of the period in which the employees render the related services are classified as short-term employee benefits, which include benefits like salaries, wages, short term compensated absences, performance incentives, etc. and are recognised as expenses in the period in which the employee renders the related service and measured accordingly.



**Jubilant Biosys Limited**

**Notes to the financial statements for the year ended 31 March 2024**

(All amounts are in INR lakhs unless otherwise stated)

(ii) Post-employment benefits:

Post employment benefit plans are classified into defined benefits plans and defined contribution plans as under:

i. Gratuity

The Company has an obligation towards gratuity, a defined benefit retirement plan covering eligible employees. The plan provides for a lump sum payment to vested employees at retirement, death while in employment or on termination of employment of an amount based on the respective employee's salary and the tenure of employment. The liability in respect of gratuity is recognised in the books of accounts based on actuarial valuation by an independent actuary. The liability in respect of all defined benefit plans and other long-term benefits is accrued in the books of account on the basis of actuarial valuation carried out by an independent actuary using the Projected Unit Credit Method. The obligation is measured at the present value of estimated future cash flows. The discount rates used for determining the present value of obligation under defined benefit plans, is based on the market yields on Government securities as at the Balance Sheet date, having maturity periods approximating to the terms of related obligations.

ii. Provident fund

The Company makes contribution to the recognised provident fund of its employees in India, provident fund is deposited with Regional Provident Fund Commissioner. This is treated as defined contribution plan. The Company's contribution to the provident fund is charged to Statement of Profit and Loss.

iii. Other long-term employee benefits (Compensated absences):

As per the Company's policy, eligible leaves can be accumulated by the employees and carried forward to future periods to either be utilised during the service, or encashed. Encashment can be made during service, on early retirement, on withdrawal of scheme, at resignation and upon death of the employee. Accumulated compensated absences are treated as other long-term employee benefits. The liability in respect of compensated absences is recognised in the books of accounts based on actuarial valuation by an independent actuary.

iv. Termination benefits:

Termination benefits are recognised as an expense when, as a result of a past event, the Company has a present obligation that can be estimated reliably, and it is probable that an outflow of economic benefits will be required to settle the obligation.

Remeasurement gains and losses in respect of other long term benefits are recognized in the statement of Profit and Loss in the year in which they arise. Remeasurement gains and losses in respect of all defined benefit plans arising from experience adjustments and changes in actuarial assumptions are recognised in the period in which they occur, directly in other comprehensive income. They are included in other equity in the Statement of Changes in Equity and in the Balance Sheet. Changes in the present value of the defined benefit obligation resulting from plan amendments or curtailments are recognised immediately in profit or loss as past service cost. Gains or losses on the curtailment or settlement of any defined benefit plan are recognised when the curtailment or settlement occurs.

Past service cost is recognised as an expense in the Statement of Profit and Loss on a straight-line basis over the average period until the benefits become vested. To the extent that the benefits are already vested immediately following the introduction of, or changes to, a defined benefit plan, the past service cost is recognised immediately in the Statement of Profit and Loss. Past service cost may be either positive (where benefits are introduced or improved) or negative (where existing benefits are reduced)

(k) Finance costs

Finance costs consist of interest and other costs that an entity incurs in connection with the borrowing of funds. Finance costs that are directly attributable to the construction or production or development of a qualifying asset are capitalized as part of the cost of that asset. Qualifying assets are assets that necessarily take a substantial period of time to get ready for their intended use or sale. All other finance costs are expensed in the period in which they occur.

Investment income earned on the temporary investment of specific borrowings pending their expenditure on qualifying assets is deducted from the finance costs eligible for capitalization. Any difference between the proceeds (net of transaction costs) and the redemption amount is recognised in the Statement of Profit and Loss over the period of the borrowings using the effective interest method Ancillary costs incurred in connection with the arrangement of borrowings are amortised over the period of such borrowings.

(l) Income tax

Income tax expense comprises current and deferred tax. It is recognised in Statement of Profit and Loss except to the extent that it relates to a business combination, or items recognised directly in equity or in OCI.

*Current tax*

Current tax comprises the expected tax payable or receivable on the taxable income or loss for the year and any adjustment to the tax payable or receivable in respect of previous years. The amount of current tax payable or receivable is the best estimate of the tax amount expected to be paid or received after considering uncertainty related to income taxes, if any. It is measured using tax rates enacted or substantively enacted at the reporting date.

Current tax assets and liabilities are offset only if there is a legally enforceable right to set off the recognised amounts, and it is intended to realise the asset and settle the liability on a net basis or simultaneously.



## Jubilant Biosys Limited

### Notes to the financial statements for the year ended 31 March 2024

(All amounts are in INR lakhs unless otherwise stated)

#### *Deferred tax*

Deferred tax is recognised in respect of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for taxation purposes. Deferred tax is not recognized for

- i. temporary differences related to freehold land and investments in subsidiaries, to the extent that the Company is able to control the timing of the reversal of the temporary differences and it is probable that they will not reverse in the foreseeable future; and
- ii. taxable temporary differences arising on the initial recognition of goodwill.

Deferred tax assets (DTA) include Minimum alternate tax (MAT) paid in accordance with the tax laws in India, which is likely to give future economic benefits in the form of availability of set off against future income tax liability.

Deferred tax assets are recognised for unused tax losses, unused tax credits and deductible temporary differences to the extent that it is probable that future taxable profits will be available against which they can be used. Unrecognised deferred tax assets are reassessed at each reporting date and recognised to the extent that it has become probable that future taxable profits will be available against which they can be used. Deferred tax is measured at the tax rates that are expected to apply to the period when the asset is realised or the liability is settled, based on the laws that have been enacted or substantively enacted by the reporting date. The measurement of deferred tax reflects the tax consequences that would follow from the manner in which the Company expects, at the reporting date, to recover or settle the carrying amount of its assets and liabilities.

Deferred tax assets and liabilities are offset only if there is a legally enforceable right to set off the recognised amounts, and it is intended to realise the asset and settle the liability on a net basis or simultaneously.

#### **(m) Leases**

##### **(i) Company as a lessee**

The Company assesses whether a contract contains a lease, at inception of a contract. A contract is, or contains, a lease if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. To assess whether a contract conveys the right to control the use of an identified asset, the Company assesses whether: (1) the contract involves the use of an identified asset; (2) the Company has substantially all of the economic benefits from use of the asset through the period of the lease; and (3) the Company has the right to direct the use of the asset. The Company's lease asset classes primarily consist of leases for Land, buildings and vehicles which typically run for a period of 3 to 99 years, with an option to renew the lease after that date. For certain leases, the Company is restricted from entering into any sub-lease arrangements. At the date of commencement of the lease, the Company recognises a right-of-use asset and a corresponding lease liability for all lease arrangements in which it is a lessee, except for leases with a term of twelve months or less (short-term leases). For these short-term leases, the Company recognises the lease payments as an operating expense on a straight-line basis over the term of the lease. Right-of-use assets and lease liabilities includes the options to extend or terminate the lease when it is reasonably certain that they will be exercised.

The right-of-use assets are initially recognised at cost, which comprises the initial amount of the lease liability adjusted for any lease payments made at or prior to the commencement date of the lease plus any initial direct costs less any lease incentives. They are subsequently measured at cost less accumulated depreciation and impairment losses, if any. Right-of-use assets are depreciated from the commencement date on a straight-line basis over the shorter of the lease term and useful life of the underlying asset. Right-of-use assets are tested for impairment whenever there is any indication that their carrying amounts may not be recoverable. Impairment loss, if any, is recognised in the Statements of Profit or Loss and Other Comprehensive Income.

The lease liability is initially measured at amortised cost at the present value of the future lease payments. The lease payments are discounted using the interest rate implicit in the lease or, if not readily determinable, using the incremental borrowing rates based on information available as at the date of commencement of the lease. Lease liabilities are remeasured with a corresponding adjustment to the related right-of-use asset if the Company changes its assessment of whether it will exercise an extension or a termination option. Lease liability and right-of-use asset have been separately presented in the Balance Sheet and lease payments have been classified as financing cash flows.

Ind AS 116 requires lessees to determine the lease term as the non-cancellable period of a lease adjusted with any option to extend or terminate the lease, if the use of such option is reasonably certain. The Company makes an assessment on the expected lease term on a lease-by-lease basis and thereby assesses whether it is reasonably certain that any options to extend or terminate the contract will be exercised. In evaluating the lease term, the Company considers factors such as any significant leasehold improvements undertaken over the lease term, costs relating to the termination of the lease and the importance of the underlying asset to Company's operations taking into account the location of the underlying asset and the availability of suitable alternatives. The lease term in future periods is reassessed to ensure that the lease term reflects the current economic circumstances.

##### **(n) Foreign currency translation**

###### *Functional and presentation currency*

The functional currency of the Company is the Indian rupee. These financial statements are presented in Indian rupees.

###### *Transactions and balances*

Foreign currency transactions are translated into the functional currency using the exchange rates at the dates of the transactions. Foreign exchange gains and losses resulting from the settlement of such transactions and from the translation of monetary assets and liabilities denominated in foreign currencies at Balance Sheet date exchange rates are generally recognised in Statement of Profit and Loss.

Non-monetary items that are measured at fair value in a foreign currency are translated using the exchange rates at the date when the fair value was determined. Translation differences on assets and liabilities carried at fair value are reported as part of the fair value gain or loss. For example, translation differences on non-monetary assets such as equity investments classified as FVOCI are recognised in other comprehensive income (OCI).



**Jubilant Biosys Limited**

**Notes to the financial statements for the year ended 31 March 2024**

**(All amounts are in INR lakhs unless otherwise stated)**

**(o) Earnings per share**

*Basic earnings per share*

Basic earnings per share is calculated by dividing:

- i. the profit attributable to owners of the Company
- ii. by the weighted average number of equity shares outstanding during the financial year, adjusted for bonus elements in equity shares issued during the year and excluding treasury shares

*Diluted earnings per share*

Diluted earnings per share adjusts the figures used in the determination of basic earnings per share to take into account:

- i. the after income tax effect of interest and other financing costs associated with dilutive potential equity shares, and
- ii. the weighted average number of additional equity shares that would have been outstanding assuming the conversion of all dilutive potential equity shares.

**(p) Measurement of fair values**

A number of the accounting policies and disclosures require measurement of fair values, for both financial and non-financial assets and liabilities. Fair values are categorised into different levels in a fair value hierarchy based on the inputs used in the valuation techniques as follows:

Level 1: quoted prices (unadjusted) in active markets for identical assets or liabilities.

Level 2: inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly (i.e. as prices) or indirectly (i.e. derived from prices).

Level 3: inputs for the asset or liability that are not based on observable market data (unobservable inputs).

The Company has an established framework with respect to measurement of fair values. This includes a finance team that has overall responsibility for overseeing all significant fair value measurements, including Level 3 fair values.

The finance team regularly reviews significant unobservable inputs and valuation adjustments. If third party information is used to measure fair values, then the finance team assesses the evidence obtained from the third parties to support the conclusion that these valuations meet the requirements of Ind AS, including the level in the fair value hierarchy in which the valuations should be classified.

When measuring the fair value of an asset or a liability, the Company uses observable market data as far as possible. If the inputs used to measure the fair value of an asset or a liability fall into different levels of the fair value hierarchy, then the fair value measurement is categorised in its entirety in the same level of the fair value hierarchy as the lowest level input that is significant to the entire measurement.

The Company recognises transfers between levels of the fair value hierarchy at the end of the reporting period during which the change has occurred.

Further information about the assumptions made in measuring fair values used in preparing these financial statements is included in the respective notes.

**(q) Critical estimates and judgements**

The preparation of Financial Statements requires management to make judgments, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses. Actual results may differ from these estimates.

Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected. In particular, information about significant areas of estimation uncertainty and critical judgments in applying accounting policies that have the most significant effect on the amounts recognized in the financial statements is included in the following notes.

- i. Revenue recognition: measurement of transaction price
- ii. Assessment of useful life of property, plant and equipment and intangible asset
- iii. Fair value measurement
- iv. Recognition and estimation of deferred tax
- v. Impairment assessment of financial assets and non-financial assets
- vi. Estimation of assets and obligations relating to employee benefits
- vii. Recognition and measurement of contingency: Key assumption about the likelihood and magnitude of an outflow of resources
- viii. Lease classification

**(r) Operating segment**

The Board of Directors of the Company have been identified as the Chief operating decision maker (CODM) as defined by Ind AS 108, Operating Segments. Operating Segments have been defined and presented based on the regular review by the CODM to assess the performance of segment and to make decision about allocation of resources. Accordingly, the Company has determined drug discovery services as the only reportable segment.

**(s) Recent accounting pronouncements**

Ministry of Corporate Affairs ("MCA") notifies new standard or amendments to the existing standards under Companies (Indian Accounting Standards) Rules as issued from time to time. For the year ended 31 March 2024, MCA has not notified any new standards or amendments to the existing standards applicable to the Company.





**Jubilant Biosys Limited**

Notes to the financial statements for the year ended 31 March 2024

(All amounts are in INR lakhs unless otherwise stated)

**Note 3: Property, plant and equipment and capital work in progress**

Description	Lab equipment	Furniture and fixtures	Leasehold Improvements	Office equipment	Total	Capital work- in-progress
<b>Gross carrying value</b>						
As at 1 April 2022	21,401.90	496.10	5,439.58	2,175.65	29,513.23	897.92
Additions	3,891.32	37.41	139.11	750.39	4,818.23	14,238.12
Deductions/transfers	(1,249.63)	(51.57)	(85.89)	(220.96)	(1,608.05)	(4,998.56)
<b>Gross carrying value as at 31 March 2023</b>	<b>24,043.59</b>	<b>481.94</b>	<b>5,492.80</b>	<b>2,705.08</b>	<b>32,723.41</b>	<b>10,137.48</b>
Accumulated depreciation as at 1 April 2022	4,111.36	247.32	583.17	725.64	5,667.49	-
Depreciation charge for the year	1,964.84	27.89	539.10	373.81	2,905.64	-
Deductions	(1,157.11)	(46.56)	(85.89)	(204.92)	(1,494.48)	-
<b>Accumulated depreciation as at 31 March 2023</b>	<b>4,919.09</b>	<b>228.65</b>	<b>1,036.38</b>	<b>894.53</b>	<b>7,078.65</b>	<b>-</b>
<b>Net carrying amount as at 31 March 2023</b>	<b>19,124.50</b>	<b>253.29</b>	<b>4,456.42</b>	<b>1,810.55</b>	<b>25,644.76</b>	<b>10,137.48</b>

Description	Lab equipment	Furniture and fixtures	Leasehold Improvements	Office equipment	Total	Capital work- in-progress
<b>Gross carrying value</b>						
As at 1 April 2023	24,043.59	481.94	5,492.80	2,705.08	32,723.41	10,137.48
Additions	10,271.43	179.14	3,025.55	2,019.43	15,495.55	6,580.86
Deductions/transfers	(822.12)	(22.88)	-	(64.61)	(909.61)	(15,772.38)
<b>Gross carrying value as at 31 March 2024</b>	<b>33,492.90</b>	<b>638.20</b>	<b>8,518.35</b>	<b>4,659.90</b>	<b>47,309.35</b>	<b>945.96</b>
Accumulated depreciation as at 1 April 2023	4,919.09	228.65	1,036.38	894.53	7,078.65	-
Depreciation charge for the year	2,424.69	34.86	808.36	498.74	3,766.65	-
Deductions	(766.42)	(21.74)	-	(61.04)	(849.20)	-
<b>Accumulated depreciation as at 31 March 2024</b>	<b>6,577.36</b>	<b>241.77</b>	<b>1,844.74</b>	<b>1,332.23</b>	<b>9,996.10</b>	<b>-</b>
<b>Net carrying amount as at 31 March 2024</b>	<b>26,915.54</b>	<b>396.43</b>	<b>6,673.61</b>	<b>3,327.67</b>	<b>37,313.25</b>	<b>945.96</b>

**Notes:**

- (1) Finance cost amounting to INR 251.54 lakhs (31 March 2023: INR 52.98 lakhs) has been capitalised in property, plant and equipment.
- (2) Capital work in progress mainly comprises of Lab equipments and building which are under installation/ construction at the reporting date.
- (3) Refer note 45 for informaion on property, plant and equipment provided as security by the Company.
- (4) None of the assets under property, plant and equipment have been revalued during the year by the Company.
- (5) The Company does not hold any Benami property under the Benami Transactions (Prohibition) Act, 1988 (as ammended). Refer note 46 (3).



**Jubilant Biosys Limited**

**Notes to the financial statements for the year ended 31 March 2024**

**(All amounts are in INR lakhs unless otherwise stated)**

**Note 4: Other intangible assets**

<b>Description</b>	<b>Software</b>
<b>Gross carrying amount</b>	
As at 1 April 2022	425.98
Additions	173.34
Deductions	-
<b>Gross carrying value as at 31 March 2023</b>	<b>599.32</b>
<b>Accumulated amortisation as at 1 April 2022</b>	200.04
Amortisation for the year	63.48
Deductions/adjustments	-
<b>Accumulated amortisation as at 31 March 2023</b>	<b>263.52</b>
<b>Net carrying amount as at 31 March 2023</b>	<b>335.80</b>
<hr/>	
<b>Description</b>	<b>Software</b>
<b>Gross carrying amount</b>	
As at 1 April 2023	599.32
Additions	95.62
Deductions	-
<b>Gross carrying value as at 31 March 2024</b>	<b>694.94</b>
<b>Accumulated amortisation as at 1 April 2023</b>	263.52
Amortisation for the year	89.86
Deductions/adjustments	-
<b>Accumulated amortisation as at 31 March 2024</b>	<b>353.38</b>
<b>Net carrying amount as at 31 March 2024</b>	<b>341.56</b>

(1) None of the intangible assets have been revalued during the year by the Company.

(Page left blank intentionally)



**Jubilant Biosys Limited**

Notes to the financial statements for the year ended 31 March 2024

(All amounts are in INR lakhs unless otherwise stated)

**Capital work-in-progress ageing schedule:**

Ageing for capital work-in-progress as at 31 March 2023 is as follows:

	Amount in capital work-in-progress for a period of				Total
	Less than 1 year	1-2 years	2-3 years	More than 3 years	
Projects in progress	8,797.61	1,082.26	212.91	44.70	10,137.48
Projects temporarily suspended	-	-	-	-	-
<b>Total capital work-in-progress</b>	<b>8,797.61</b>	<b>1,082.26</b>	<b>212.91</b>	<b>44.70</b>	<b>10,137.48</b>

Project execution plans are modulated basis capacity requirement assessment on an annual basis and all the projects are executed as per rolling annual plan.

Projects in progress as at 31 March 2023 have not exceed the estimated cost and timeline compared to their respective original plans.

Ageing for capital work-in-progress as at 31 March 2024 is as follows:

	Amount in capital work-in-progress for a period of				Total
	Less than 1 year	1-2 years	2-3 years	More than 3 years	
Projects in progress	368.05	253.87	133.20	190.84	945.96
Projects temporarily suspended	-	-	-	-	-
<b>Total capital work-in-progress</b>	<b>368.05</b>	<b>253.87</b>	<b>133.20</b>	<b>190.84</b>	<b>945.96</b>

Project execution plans are modulated basis capacity requirement assessment on an annual basis and all the projects are executed as per rolling annual plan.

Projects in progress as at 31 March 2024 have not exceed the estimated cost and timeline compared to their respective original plans.

(Page left blank intentionally)



**Jubilant Biosys Limited**

Notes to the financial statements for the year ended 31 March 2024

(All amounts are in INR lakhs unless otherwise stated)

**Note 5: Investments**

	As at 31 March 2024	As at 31 March 2023
<b>Investment in equity shares (at cost)</b>		
<b>Unquoted investments in subsidiary company, (fully paid up)</b>		
1,999,766 (31 March 2023: 1,999,766) equity shares of INR 10 each Jubilant Clinsys Limited	410.79	410.79
5,530,001 (31 March 2023: 5,530,001) equity shares with no par value Jubilant Biosys Innovative Research Services Pte Limited	4,268.43	4,268.43
<b>Unquoted investments in other company, (fully paid up)</b>		
<b>Investment in equity shares (at amortised cost)</b>		
64,660 (31 March 2023: Nil) equity shares of INR 10 each O2 Renewable Energy XVI Private Limited	0.47	-
<b>Investment in debentures (at amortised cost)</b>		
5,819 (31 March 2023: Nil) 0.01% compulsorily convertible debentures of INR 1,000 each O2 Renewable Energy XVI Private Limited	4.24	-
<b>Total non-current investments</b>	<b>4,683.93</b>	<b>4,679.22</b>
<b>Aggregate amount of unquoted investments</b>	4,683.93	4,679.22
<b>Aggregate amount of impairment in the value of investments</b>	-	-

**Note:**

Pursuant to Securities Subscription and Shareholder's agreement ("SSSA") with O2 Energy SG Pte Limited and O2 Renewable Energy XVI Private Limited ("O2") dated 2 January 2024, the Company has acquired 1.79% stake of O2, for the purpose of setting up a solar power plant with capacity of 1.57 MW, for captive consumption of power. Pursuant to that, the Company has made investment of INR 64.66 lakhs in O2, representing investment in 64,660 number of Equity shares of INR 10 each and 5,819 number of 0.01% Compulsorily Convertible Debenture of INR 1,000 each. Further, the Company has also entered into a Power Purchase Agreement ('PPA') with O2 to procure 100% of the output of solar energy produced for next 25 years as per the rates negotiated in agreement. As per the SSSA, in the event of termination of the contracts or completion of the PPA term, the Company will receive nominal value of its investment without any share of profit/ loss in the associate. Accordingly, the investment amount has been amortised to give the effect of expected fixed return on such investment due to the difference in agreement rate and existing government grid rates.

**Note 6: Loans**

	As at 31 March 2024		As at 31 March 2023	
	Current	Non- current	Current	Non- current
<b>Unsecured, considered good</b>				
Loan to related parties*	-	10,402.15	-	16,117.00
Loan to employees**	62.21	-	66.80	-
<b>Total loans</b>	<b>62.21</b>	<b>10,402.15</b>	<b>66.80</b>	<b>16,117.00</b>

\*Refer note 34 and 39.

\*\*Company has not granted any loans to any of its directors and any officers or any of them either severally or jointly with any other person.

**Note 7: Other financial assets**

	As at 31 March 2024		As at 31 March 2023	
	Current	Non- current	Current	Non- current
Security deposits*	-	431.63	-	352.98
Deposits with maturity after 12 months from the reporting date**	-	-	-	13.39
Export incentive receivable	36.77	-	-	-
Unbilled revenue	569.35	-	835.33	-
Interest receivable	3.86	-	0.74	-
Interest receivable from related party (Refer note 34)	79.48	-	10.51	-
Short term deposit	1.10	-	1.10	-
Other recoverable from related party (Refer note 34)	742.98	-	458.96	-
<b>Total other financial assets</b>	<b>1,433.54</b>	<b>431.63</b>	<b>1,306.64</b>	<b>366.37</b>

\*Security deposit receivable from related parties (Refer note 34)

\*\*The deposits have restricted use.



**Jubilant Biosys Limited**

Notes to the financial statements for the year ended 31 March 2024

(All amounts are in INR lacs unless otherwise stated)

**Note 8: Deferred tax**

Deferred income tax reflect the net tax effect of temporary difference between carrying amount of assets and liabilities for financial reporting purpose and the amount used for income tax purpose. Significant component of the Company's net deferred income tax are as follows:

**Deferred tax assets:**

	As at 31 March 2024	As at 31 March 2023
Provision for compensated absences and gratuity	466.56	419.99
Expenditure allowed on actual payment basis	208.72	133.18
Allowance/ expected credit allowance	160.55	5.67
Lease liability	138.02	108.23
Others	1.34	4.85
	<u>975.19</u>	<u>671.92</u>

**Deferred tax liabilities:**

	As at 31 March 2024	As at 31 March 2023
Accelerated depreciation for tax purposes	612.68	384.30
	<u>612.68</u>	<u>384.30</u>

**Reflected in the balance sheet as follows:**

	As at 31 March 2024	As at 31 March 2023
Deferred tax assets	975.19	671.92
Deferred tax liabilities	612.68	384.30
Deferred tax assets, net	<u>362.51</u>	<u>287.62</u>

**Reconciliation of deferred tax assets (net):**

	As at 31 March 2024	As at 31 March 2023
Balance at the commencement of the year	287.62	450.76
Expense during the period recognised in statement of profit or loss	66.59	(181.06)
Credit during the period recognised in other comprehensive income	8.30	17.92
Balance at the end of the year	<u>362.51</u>	<u>287.62</u>

**Note 9: Other non-current assets**

	As at 31 March 2024	As at 31 March 2023
<b>Unsecured, considered good</b>		
Capital advances	171.47	332.47
Prepaid expenses	57.49	-
<b>Total other non-current assets</b>	<u>228.96</u>	<u>332.47</u>

**Note 10: Inventories**

	As at 31 March 2024	As at 31 March 2023
<b>Valued at lower of cost and net realisable value</b>		
Project-in-progress	1,178.94	119.15
Stores and spares	52.78	68.11
<b>Total inventories</b>	<u>1,231.72</u>	<u>187.26</u>

**Note 11: Trade receivables**

	As at 31 March 2024	As at 31 March 2023
<b>Trade receivables, Unsecured</b>		
Trade receivables, considered	7,637.49	8,362.10
Receivables from related parties (Refer note 34)	689.22	1,700.35
Trade receivables - which have significant increase in credit risk	637.93	22.54
Less: Expected credit loss allowance (Refer note 31)	(637.93)	(22.54)
<b>Total trade receivables</b>	<u>8,326.71</u>	<u>10,062.45</u>



Jubilant Biosys Limited  
Notes to the financial statements for the year ended 31 March 2024  
(All amounts are in INR lakhs unless otherwise stated)

Trade receivables ageing schedule as at 31 March 2024:

	Not due	Outstanding for following periods from due date of payment					Total
		Less than 6 Months	6 months-1 year	1-2 years	2-3 years	More than 3 years	
Undisputed trade receivables – considered good	4,160.94	2,885.57	158.84	1,105.17	113.13	1.84	8,425.49
Undisputed trade receivables – which have significant increase in credit risk	-	-	-	-	-	-	-
Undisputed trade receivable – credit impaired	-	-	-	539.15	-	-	539.15
Disputed trade receivables – considered good	-	-	-	-	-	-	-
Disputed trade receivables – which have significant increase in credit risk	-	-	-	-	-	-	-
Disputed trade receivables – credit impaired	-	-	-	-	-	-	-
	<u>4,160.94</u>	<u>2,885.57</u>	<u>158.84</u>	<u>1,644.32</u>	<u>113.13</u>	<u>1.84</u>	<u>8,964.64</u>
Less: Expected credit loss allowance							(637.93)
<b>Total trade receivables</b>							<u><u>8,326.71</u></u>

Trade receivables ageing schedule as at 31 March 2023:

	Not due	Outstanding for following periods from due date of payment					Total
		Less than 6 Months	6 months-1 year	1-2 years	2-3 years	More than 3 years	
Undisputed trade receivables – considered good	4,923.55	4,229.45	787.67	117.96	0.35	3.47	10,062.45
Undisputed trade receivables – which have significant increase in credit risk	-	-	-	-	-	-	-
Undisputed trade receivable – credit impaired	-	-	0.63	-	-	21.91	22.54
Disputed trade receivables – considered good	-	-	-	-	-	-	-
Disputed trade receivables – which have significant increase in credit risk	-	-	-	-	-	-	-
Disputed trade receivables – credit unpaired	-	-	-	-	-	-	-
	<u>4,923.55</u>	<u>4,229.45</u>	<u>788.30</u>	<u>117.96</u>	<u>0.35</u>	<u>25.38</u>	<u>10,084.99</u>
Less: Expected credit loss allowance							(22.54)
<b>Total trade receivables</b>							<u><u>10,062.45</u></u>

Note: 12 (a) Cash and cash equivalents

	As at 31 March 2024	As at 31 March 2023
<b>Balances with banks</b>		
- in current accounts	1,795.67	463.75
- deposit accounts with original maturity up to three months	1,250.00	-
<b>Cash on hand</b>	0.51	1.50
Funds in transit	115.61	-
<b>Total cash and cash</b>	<u>3,161.79</u>	<u>465.25</u>



**Jubilant Biosys Limited**  
**Notes to the financial statements for the year ended 31 March 2024**  
(All amounts are in INR lakhs unless otherwise stated)

**Note 12 (b) Other bank balances**

	As at 31 March 2024	As at 31 March 2023
Deposits accounts with maturity up to twelve months from the reporting date- held as margin money*	0.36	0.36
<b>Total other bank balance</b>	<b>0.36</b>	<b>0.36</b>

\*The amount of other bank balances have restricted use.

**Note 13: Other current assets**

	As at 31 March 2024	As at 31 March 2023
Prepaid expenses	1,023.35	598.88
Balances with government authorities	2,813.13	4,530.65
Advance to employees	16.94	19.69
Advance for supply of goods and services*	566.73	152.41
<b>Total other current assets</b>	<b>4,420.15</b>	<b>5,301.63</b>
*Advance for supply of goods and services to related parties (Refer note 34)	497.46	-

**Note 14: Equity share capital**

	As at 31 March 2024	As at 31 March 2023
<b>Authorised</b>		
258,000,000 equity shares of INR 10 each (31 March 23: 258,000,000 equity shares of INR 10 each)	25,800.00	25,800.00
	<b>25,800.00</b>	<b>25,800.00</b>
<b>Issued, subscribed and paid up</b>		
252,140,534 equity shares of INR 10 each (31 March 23: 252,140,534 equity shares of INR 10 each)	25,214.05	25,214.05
	<b>25,214.05</b>	<b>25,214.05</b>

**a) Reconciliation of shares outstanding at the beginning and at the end of the reporting period**

Particulars	31 March 2024		31 March 2023	
	Number of shares	INR in lakhs	Number of shares	INR in lakhs
<b>Equity shares</b>				
At the commencement of the year	252,140,534	25,214.05	252,140,534	25,214.05
Add: Issued during the year	-	-	-	-
At the end of the year	252,140,534	25,214.05	252,140,534	25,214.05

**b) Rights, preferences and restriction attached to equity shares:-**

The Company has a single class of equity shares. Accordingly, all equity shares rank equally with regard to dividends and share in the Company's residual assets. The equity shares are entitled to receive dividends as declared from time to time. The voting rights of equity shareholders on a poll (not on show of hands) are in proportion to its share of the paid-up equity capital of the Company. Voting rights can not be exercised in respect of shares on which any call or other sums presently payable have not been paid.

In the event of liquidation of the Company, the holders of equity shares will be entitled to receive any of the remaining assets of the Company, the distribution will be in proportion to the number of equity shares held by shareholders.

**c) Details of shareholders holding more than 5% shares in the company**

Particulars	As at 31 March 2024		As at 31 March 2023	
	Number of shares	% holding	Number of shares	% holding
Equity shares of INR 10 each fully paid up held by Jubilant Pharmova Limited, holding company (including 6 shares held by Jubilant Pharmova Limited jointly with 6 different individuals)	251,890,534	99.90%	251,890,534	99.90%

**d) Equity shares held by holding company/ultimate holding company is set out below:**

	As at 31 March 2024	As at 31 March 2023
Jubilant Pharmova Limited	251,890,534	251,890,534

e) During the five years immediately preceding the financials year 31 March 2024, the Company has not issued any bonus shares and shares for consideration other than cash. The Company has also not bought back any shares.



**Jubilant Biosys Limited**  
**Notes to the financial statements for the year ended 31 March 2024**  
**(All amounts are in INR lakhs unless otherwise stated)**

**14 (2) Nature and purpose of other Equity**

**Capital reserve**

Accumulated capital surplus not available for distribution of dividend and expected to remain invested permanently. It includes share based payment transaction cost as charged by the holding company.

**Capital redemption reserve**

Capital redemption reserve represents the unutilized accumulated amount set aside at the time of redemption of shares. This reserve is utilized in accordance with the provisions of the Act.

**Remeasurement of defined benefit obligation**

Remeasurement of defined benefit obligation comprises actuarial gains and losses.

**Securities Premium**

The unutilized accumulated excess of issue price over face value on issue of shares. This reserves is utilised in accordance with the provisions of the act.

**Amalgamation Adjustment Deficit Account**

In financial year 2019-20, pursuant to the Hon'ble National Company Law Tribunal, Allahabad (NCLT) Order, the difference between the book value of the assets, liabilities and reserves as reduced by the face value of the equity shares and compulsorily convertible preference shares to be issued by the transferee company, has been accounted to amalgamation adjustment deficit account of INR 6,162.22 lakhs.

**Retained Earnings**

Retained earnings represent the amount of accumulated earnings of the Company and re-measurement differences on defined benefit plans.

**Note 15: Non-current borrowings**

	As at 31 March 2024	As at 31 March 2023
<b>Term loan from bank</b>		
Indian rupee loans (secured)	10,968.73	15,121.91
<b>Total non-current borrowings</b>	<b>10,968.73</b>	<b>15,121.91</b>

**Note 15 (A): Short-term borrowings**

	As at 31 March 2024	As at 31 March 2023
<b>Current maturities of non-current borrowings</b>		
Indian rupee loans (secured)	2,448.19	1,875.00
<b>Loan repayable on demand from banks (secured):</b>		
- Working capital loan	-	1,850.00
	<b>2,448.19</b>	<b>3,725.00</b>

**Nature of security and other terms of repayment of borrowings as on 31 March 2024**

Indian rupee term loans outstanding amount of INR 5,059.98 lakhs (31 March 2023: 7,031.25 lakhs) from The Hongkong and Shanghai Banking Corporation Limited are secured by a first pari-passu charge on all movable assets of the Company located at Noida and Greater Noida, both present and future. The Indian rupee term loan is repayable in 16 equal quarterly installments from quarter ended 31 March 2023.

Indian rupee term loans outstanding amount of INR 8,356.93 lakhs (31 March 2023: 9,965.66) from The Hongkong and Shanghai Banking Corporation Limited are secured by a first pari-passu charge on all movable assets of the Company located at Noida and Greater Noida, both present and future. The Indian rupee term loan is repayable in 16 equal quarterly installments from 17 February 2025. The sanction limit of the term loan is INR 12,500.00 lakhs. The loan amount drawdown during the year Rs. 1,720.27 lakhs and repaid INR 3,329 lakhs.

The Indian rupee term loans carry floating interest rate calculated in accordance with the terms of the arrangement which is a specified benchmark rate (reset at periodic intervals), adjusted for agreed spread. During the year ended 31 March 2024, the interest rate on Indian currency loans ranging from 8.84% to 9.54% p.a.

The Company has availed working capital facility of INR 2,500 lakhs (Previous year INR 2,500 lakhs) from The Hongkong and Shanghai Banking Corporation Limited. The facility is secured by way of first pari-passu charge on all current assets of the Company, both present and future. During the year ended 31 March 2024, the interest rate on Indian currency loans ranging from 8.18% to 9.00% p.a..





**Jubilant Biosys Limited**

Notes to the financial statements for the year ended 31 March 2024

(All amounts are in INR lakhs unless otherwise stated)

**Reconciliation of movement of liabilities to cash flow arising from financing activities**

	As at 31 March 2024	As at 31 March 2023
As at beginning of the year	22,767.37	10,335.84
Movement due to cash transactions as per the statement of cash flows	(8,312.57)	9,543.82
Movement due to non cash transactions:		
- Finance cost incurred	1,473.75	1,210.24
- Finance cost capitalised	251.54	52.98
- New car lease added	30.74	62.51
- Closure of car lease	(21.47)	-
- Lease modification	1,180.84	1,561.98
<b>As at end of the year</b>	<b>17,370.20</b>	<b>22,767.37</b>

**Note 16: Provisions**

	As at 31 March 2024		As at 31 March 2023	
	Current	Non-current	Current	Non-current
Provision for gratuity (refer note 29)	146.87	1,072.89	131.44	946.47
Provision for earned leave encashment (refer note 29)	92.79	540.02	86.44	504.37
<b>Total provisions</b>	<b>239.66</b>	<b>1,612.91</b>	<b>217.88</b>	<b>1,450.84</b>

**Note 17: Trade payables**

	As at 31 March 2024	As at 31 March 2023
Total outstanding due to micro and small enterprises	418.69	400.96
Total outstanding due to other than micro and small enterprises	2,168.35	2,460.42
<b>Total trade payables</b>	<b>2,587.04</b>	<b>2,861.38</b>
Amount payable to related parties included in above (refer note 34)	372.33	355.38

**Micro and Small Enterprises**

There are no micro and small enterprises, to whom the company owes dues, which are outstanding for more than 45 days/credit period as at the end of year. The information as required to be disclosed in relation to micro and small enterprises has been determined to the extent such parties have been identified on the basis of information available with the Company.

	As at 31 March 2024	As at 31 March 2023
The principal amount remaining unpaid to any supplier as at the end of the year	418.69	400.96
The interest due on principal amount remaining unpaid to any supplier as at the end of the year	-	-
The amount of interest paid by the Company in terms of section 16 of the Micro, Small and Medium Enterprises Development Act, 2006 (MSMED Act), along with the amount of the payment made to the supplier beyond the appointed day during the year	-	-
The amount of interest due and payable for the period of delay in making payment (which have been paid but beyond the appointed day during the year) but without adding the interest specified under the MSMED Act	-	-
The amount of interest accrued and remaining unpaid at the end of the year	-	-
The amount of further interest remaining due and payable even in the succeeding years, until such date when the interest dues as above are actually paid to the small enterprise, for the purpose of disallowance as a deductible expenditure under the MSMED Act	-	-

**Trade payables ageing schedule as at 31 March 2024:**

	Unbilled	Not due	Outstanding for following periods from due date of payment				Total
			Less than 1 year	1-2 years	2-3 years	More than 3 years	
Micro enterprises and small enterprises	0.41	410.26	4.45	3.57	-	-	418.69
Other than micro enterprises and small enterprises	299.47	1,134.20	720.77	13.91	-	-	2,168.35
Disputed dues - micro enterprises and small enterprises	-	-	-	-	-	-	-
Disputed dues - other than micro enterprises and small enterprises	-	-	-	-	-	-	-
	<b>299.88</b>	<b>1,544.46</b>	<b>725.22</b>	<b>17.48</b>	<b>-</b>	<b>-</b>	<b>2,587.04</b>



**Jubilant Biosys Limited**

Notes to the financial statements for the year ended 31 March 2024

(All amounts are in INR lakhs unless otherwise stated)

**Trade payables ageing schedule as at 31 March 2023:**

	Unbilled	Not dne	Outstanding for following periods from due date of payment				Total
			Less than 1 year	1-2 years	2-3 years	More than 3 years	
Micro enterprises and small enterprises	-	88.87	306.28	5.81	-	-	400.96
Other than micro enterprises and small enterprises	354.47	383.42	1,690.29	32.24	-	-	2,460.42
Disputed dues - micro enterprises and small enterprises	-	-	-	-	-	-	-
Disputed dues - other than micro enterprises and small enterprises	-	-	-	-	-	-	-
	<b>354.47</b>	<b>472.29</b>	<b>1,996.57</b>	<b>38.05</b>	<b>-</b>	<b>-</b>	<b>2,861.38</b>

**Note 18: Other current financial liabilities**

	As at 31 March 2024	As at 31 March 2023
Interest accrued	73.11	80.29
Capital creditors*	1,424.74	2,140.16
Employee benefits payable	968.80	710.96
Other payables	193.26	-
<b>Total other current financial liabilities</b>	<b>2,659.91</b>	<b>2,931.41</b>
*Amount payable to related parties included above (Refer note 34)	-	212.92

**Note 19: Other current liabilities**

	As at 31 March 2024	As at 31 March 2023
Advance from customers	1,472.85	333.51
Statutory dues payables	430.48	380.93
Income received in advance/ unearned income	-	43.85
<b>Total other current liabilities</b>	<b>1,903.33</b>	<b>758.29</b>

**Note 20: Revenue from operations**

	Year ended 31 March 2024	Year ended 31 March 2023
Sale of goods and services*	45,049.29	54,478.22
Other operating revenue		
- Scrap sales	103.94	25.15
- Others	39.05	11.42
<b>Total revenue from operations</b>	<b>45,192.28</b>	<b>54,514.79</b>

\* Includes sale of products delivered as a part of service contract INR 1,718.96 lakhs (31 March 2023: INR 3,802.57 lakhs)

In the following table, revenue from sale of services is disaggregated by primary geographical market

Primary geographical markets	Year ended 31 March 2024	Year ended 31 March 2023
America	36,875.26	41,957.13
India	47.55	291.28
Europe	5,178.85	7,239.44
Rest of the world	2,947.63	4,990.37
<b>Total sale of goods and services</b>	<b>45,049.29</b>	<b>54,478.22</b>
<b>Major service lines</b>		
Full time equivalent (FTE)	36,808.64	43,352.35
Fee for service (FFS)	8,240.65	11,125.87
	<b>45,049.29</b>	<b>54,478.22</b>



**Jubilant Biosys Limited**

Notes to the financial statements for the year ended 31 March 2024

(All amounts are in INR lakhs unless otherwise stated)

**Contract Balances**

Particulars	As at	As at
	31 March 2024	31 March 2023
Trade receivables	8,326.71	10,062.45
Unbilled revenue	569.35	835.33
Contract liabilities	1,472.85	377.36

The unbilled revenue primarily relate to the Company's right to consideration for work completed but not billed on reporting date. The unbilled revenue are transferred to receivables when company issues an invoice to the customer. The contract liabilities primarily relate to the advance received from customers and income received in advance/unearned income, revenue is recognised against the same as or when the performance obligation is satisfied.

Out of amount of INR 377.36 lakhs and INR 683.99 lakhs recognised in contract liabilities at the beginning of the year, INR 354.79 lakhs and INR 430.17 lakhs has been recognised as revenue for the year ended 31 March 2024 and 31 March 2023, respectively.

**Note 21: Other income**

	Year ended	Year ended
	31 March 2024	31 March 2023
Interest income	930.00	622.86
Other non-operating income	974.86	579.06
Liabilities/ provision written back	0.43	2.09
Net foreign exchange gain	46.95	567.68
<b>Total other income</b>	<b>1,952.24</b>	<b>1,771.69</b>

**Note 22: Cost of material consumed**

	Year ended	Year ended
	31 March 2024	31 March 2023
Raw material consumed	399.12	1,072.27
	<b>399.12</b>	<b>1,072.27</b>

**Note 23: Changes in inventories of work-in-progress and finished goods**

	Year ended	Year ended
	31 March 2024	31 March 2023
Opening balance		
Project-in progress	119.15	536.91
Opening balance	119.15	536.91
Closing balance		
Project-in-progress	1,178.94	119.15
Closing balance	1,178.94	119.15
<b>(Increase)/decrease in inventory</b>	<b>(1,059.79)</b>	<b>417.76</b>

**Note 24: Employee benefit expense**

	Year ended	Year ended
	31 March 2024	31 March 2023
Salaries, wages, bonus, gratuity and allowances	13,024.75	12,719.46
Contribution to provident fund	647.00	633.13
Staff welfare expenses	870.79	960.69
<b>Total employee benefit expense</b>	<b>14,542.54</b>	<b>14,313.28</b>

**Note 25: Finance costs**

	Year ended	Year ended
	31 March 2024	31 March 2023
Interest expense		
- on borrowings	1,011.02	634.81
- on lease obligation	462.73	508.77
Interest on tax	-	66.66
<b>Total finance cost</b>	<b>1,473.75</b>	<b>1,210.24</b>



**Jubilant Biosys Limited**

Notes to the financial statements for the year ended 31 March 2024

(All amounts are in INR lakhs unless otherwise stated)

**Note 26: Depreciation and amortisation expense**

	Year ended 31 March 2024	Year ended 31 March 2023
Depreciation of property, plant and equipment	3,766.65	2,905.66
Amortisation of intangible assets	89.86	63.48
Depreciation of right of use assets	1,302.88	309.27
<b>Total depreciation and amortisation expense</b>	<b>5,159.39</b>	<b>3,278.41</b>

**Note 27: Other expenses**

	Year ended 31 March 2024	Year ended 31 March 2023
Consumption of stores and spares and packing materials	10,726.57	12,765.97
Processing charges	388.06	442.97
Rent	114.16	246.86
Rates and taxes	917.59	658.53
Insurance	72.50	49.92
Advertisement and sales promotion	1,215.86	1,509.18
Travelling and conveyance	853.00	780.35
Repairs and maintenance		
Plant and machinery	924.27	906.29
Buildings	77.00	68.43
Others	430.12	357.79
Office expenses	2,604.04	2,313.82
Power and fuel	688.82	685.85
Vehicle running and maintenance	22.39	24.73
Printing and stationery	48.31	59.34
Telephone and communication charges	39.03	49.79
Staff recruitment and training	154.89	376.28
Donation (refer note no. 41)	225.40	191.05
Payments to auditors (refer note (i) below)	12.00	4.55
Legal and professional fees	1,703.57	1,124.36
Freight and forwarding	342.67	354.39
Subscription	446.31	349.63
Bank charges	21.09	22.23
Write off balances	1.76	1.10
Loss on sale/ write off of property, plant and equipment (net)	49.57	66.42
Allowance/ expected credit allowance	637.93	-
Miscellaneous expenses	-	0.20
<b>Total other expenses</b>	<b>22,716.91</b>	<b>23,410.03</b>

**(i) Payments to auditors (excluding goods and service tax)**

	Year ended 31 March 2024	Year ended 31 March 2023
<b>As auditor:</b>		
Statutory audit	11.00	3.55
<b>In other capacities</b>		
Certification fees	1.00	1.00
<b>Total payments to auditors</b>	<b>12.00</b>	<b>4.55</b>



**Jubilant Biosys Limited**  
**Notes to the financial statements for the year ended 31 March 2024**  
**(All amounts are in INR lakhs unless otherwise stated)**

**Note 28: Income tax**

The major components of income tax expense for the years ended 31 March 2024 and 31 March 2023 are:

**Statement of Profit and Loss:**

**Profit or loss section**

	Year ended 31 March 2024	Year ended 31 March 2023
<b>Current income tax:</b>		
Current income tax charge for the year	1,172.89	3,097.44
Adjustments in respect of current income tax of previous year	(47.03)	(33.83)
	<u>1,125.86</u>	<u>3,063.61</u>
<b>Deferred tax:</b>		
Relating to origination and reversal of temporary differences	(112.89)	139.89
Adjustments in respect of deferred tax of previous year	46.30	41.17
	<u>(66.59)</u>	<u>181.06</u>
<b>Income tax expense reported in the statement of profit or loss</b>	<u><u>1,059.27</u></u>	<u><u>3,244.67</u></u>

**OCI section**

Tax related to items that will not be reclassified to profit & loss: (8.30) (17.92)

**Income tax charged to OCI**

(8.30) (17.92)

**Reconciliation between average effective tax rate and applicable tax rate for 31 March 2024 and 31 March 2023:**

	Year ended 31 March 2024	Year ended 31 March 2023
Accounting profit before income tax	3,912.60	12,584.49
At India's statutory income tax rate of 25.17% (31 March 2023: 25.17%)	984.72	3,167.26
- Effect of non-deductible expenses	75.26	70.06
- Taxes of earlier years ( true ups)	(0.71)	7.35
<b>Income tax expense reported in the statement of profit and loss</b>	<u><u>1,059.27</u></u>	<u><u>3,244.67</u></u>

**Note 29: Employee benefits in respect of the Company have been calculated as under:**

**(a) Defined contribution plans**

The Company contributes to the following defined contribution plan

**(i) Provident fund\***

During the year, the Company has contributed following amount to:

\*The Company contributes share of provident fund liability and deposit it with PF Commissioner.

Particulars	Year ended 31 March 2024	Year ended 31 March 2023
Employer's contribution to provident fund	565.91	568.04

**(ii) State plans\***

During the year, the Company has contributed following amount to:

Particulars	Year ended 31 March 2024	Year ended 31 March 2023
Employer's contribution to employee state insurance	8.58	12.74

**(b) Defined benefit plans**

**(i) Gratuity**

As per Ind AS-19, Liabilities with regard to the Gratuity Plan are determined by actuarial valuation, performed by an independent actuary, at each balance sheet date using the projected unit credit method. The discount rate assumed is 7.13% p.a. (31 March 2023: 7.35% p.a.) which is determined by reference to market yield at the Balance Sheet date on Government bonds. The retirement age has been considered at 58 years (31 March 2023: 58 years) and mortality table is as per IALM (2012-14) (31 March 2023: IALM (2012-14)).

The estimates of future salary increases, considered in actuarial valuation is 10% p.a. for first three years and 6% p.a. thereafter (31 March 2023: 10% p.a. for first three years and 6% p.a. thereafter), taking into account of inflation, seniority, promotion and other relevant factors, such as supply and demand in the employment market.



**Jubilant Biosys Limited**  
**Notes to the financial statements for the year ended 31 March 2024**  
(All amounts are in INR Lakhs unless otherwise stated)

**Reconciliation of opening and closing balances of the present value of the defined benefit obligation:**

Particulars	As at	
	31 March 2024	31 March 2023
Present value of obligation at the beginning of the year	1077.91	971.57
Current service cost	196.73	183.69
Interest cost	79.23	69.95
Actuarial loss	32.98	71.19
Benefits paid	(167.09)	(218.49)
<b>Present value of obligation at the end of the year</b>	<b>1,219.76</b>	<b>1,077.91</b>

**Reconciliation of the present value of defined benefit obligation and the fair value of the plan assets:**

Particulars	As at	
	31 March 2024	31 March 2023
Present value of obligation at the end of the year	1,219.76	1,077.91
Fair value of plan assets at the end of the year	-	-
<b>Net liabilities recognised in the balance sheet</b>	<b>1,219.76</b>	<b>1,077.91</b>

**Expense recognized in the statement of profit and loss under employee benefit expense:**

Particulars	As at	
	31 March 2024	31 March 2023
Current service cost	196.73	183.69
Interest cost	79.23	69.95
<b>Expense recognised in the statement of profit and loss</b>	<b>275.96</b>	<b>253.64</b>

**Amount recognised in the statement of other comprehensive income:**

Particulars	As at	
	31 March 2024	31 March 2023
Actuarial (gain)/loss due to demographic assumption change	-	0.04
Actuarial loss due to financial assumption change	16.32	(10.72)
Actuarial loss due to experience adjustment	16.66	81.87
<b>Amount recognised in other comprehensive income</b>	<b>32.98</b>	<b>71.19</b>

Company's best estimate of contribution during next year is INR 305.68 Lakhs (31 March 2023: INR 297.30 Lakhs)

**Sensitivity analysis**

Particulars	Year ended 31 March 2024		Year ended 31 March 2023	
	0.5% increase	0.5% decrease	0.5% increase	0.5% decrease
Impact on defined benefit	37.09	(35.46)	33.15	(31.67)

The sensitivity analysis above has been determined based on reasonable possible changes of the respective assumptions occurring at the end of the year and may not be representative of the actual change. It is based on the change in the key assumption while holding all other assumption constant.

**Maturity profile of defined benefit obligation**

Particulars	As at	
	31 March 2024	31 March 2023
Within one year	146.87	131.44
Between one to three years	240.02	212.28
Between three to five years	189.48	169.52
Later than five years	643.39	564.67
<b>Total</b>	<b>1,219.76</b>	<b>1,077.91</b>

**(i) Other long term benefits (lease encashment)**

Particulars	As at	
	31 March 2024	31 March 2023
Present value of obligation at the end of the year	632.81	590.82

**Maturity profile of defined benefit obligation**

Particulars	As at	
	31 March 2024	31 March 2023
Within one year	92.79	86.45
Between one to three years	133.76	127.53
Between three to five years	113.64	111.80
Later than five years	292.62	265.04
<b>Total</b>	<b>632.81</b>	<b>590.82</b>



**Jubilant Biosys Limited**  
**Notes to the financial statements for the year ended 31 March 2024**  
(All amounts are in INR lakhs unless otherwise stated)

**Note 30: Fair value measurement**

Particulars	Note	Level of hierarchy	As at 31 March 2024			As at 31 March 2023		
			FVTPL	FVOCI	Amortised cost	FVTPL	FVOCI	Amortised cost
<b>Financial asstes</b>								
Investments*	(b)	-	-	-	4,683.93	-	-	4,679.22
Loans	(a,b)	Level 3	-	-	10,464.36	-	-	16,183.80
Other financial assets	(a,b)	-	-	-	1,865.17	-	-	1,673.01
Trade receivables	(a)	-	-	-	8,326.71	-	-	10,062.45
Cash and cash equivalents	(a)	-	-	-	3,161.79	-	-	465.25
Other bank balance	(a)	-	-	-	0.36	-	-	0.36
<b>Total financial assets</b>					<b>28,502.32</b>			<b>33,064.09</b>

\*includes investments held at cost

Particulars	Note	Level of hierarchy	As at 31 March 2024			As at 31 March 2023		
			FVTPL	FVOCI	Amortised cost	FVTPL	FVOCI	Amortised cost
<b>Financial liabilities</b>								
Borrowings	(b)	Level 3	-	-	13,416.92	-	-	18,846.91
Lease liabilities	(a,b)	-	-	-	3,880.16	-	-	3,840.17
Trade payables	(a,b)	-	-	-	2,587.04	-	-	2,861.38
Other financial liabilities	(b)	-	-	-	2,659.91	-	-	2,931.41
<b>Total financial liabilities</b>					<b>22,544.03</b>			<b>28,479.87</b>

a. Fair valuation of financial assets and liabilities with short-term maturities is considered as approximate to respective carrying amount due to the short-term maturities of these instruments.

b. Fair value of non-current financial assets and non-current financial liabilities have not been disclosed as there is no significant difference between carrying value and fair value

c. There are no transfers between Level 1, level 2 and level 3 during the year ended 31 March 2024 and 31 March 2023.

**Note 31: Financial risk management**

The Company's board of directors has overall responsibility for the establishment and oversight of the Company's risk management framework. The risk management framework is intended to ensure that risks are taken care with due diligence.

The Company's risk management policies are established to identify and analyse the risks faced by the Company, to set appropriate risk limits and controls and to monitor risks and adherence to limits. Risk management policies and systems are reviewed regularly to reflect changes in market conditions and the Company's activities. The Company, through three layers of defense namely policies and procedures, review mechanism and assurance aims to maintain a disciplined and constructive control environment in which all employees understand their roles and obligations.

The Company has exposure to the following risks arising from financial instruments:

- credit risk (see (i))
- liquidity risk (see (ii)), and
- market risk (see (iii))
- interest rate risk (see (iv))

**(i) Credit risk**

Credit risk is the risk of financial loss to the Company if a customer or counterparty to a financial instrument fails to meet its contractual obligations, and arises principally from the Company's receivables from customers and from its financing activities, including deposit with banks, investments, foreign exchange transactions and other financial instruments.

The carrying amount of financial assets represents the maximum credit exposure.

**Trade receivables and other financial assets**

The Company has established a credit policy under which each new customer is analysed individually for creditworthiness before the Company's standard payment and delivery terms and conditions are offered. The Company's review includes external ratings, if they are available, financial statements, credit agency information, industry information and business intelligence. Sale limits are established for each customer and reviewed annually. Any sales exceeding those limits require approval from the appropriate authority as per policy.

The Company limits its exposure to credit risk from trade receivables by establishing a maximum payment period of three months for external customers.

In monitoring customer credit risk, customers are grouped according to their credit characteristics, including whether they are an individual or a legal entity, whether they are institutional, dealers or end-user customer, their geographic location, industry, trade history with the Company and existence of previous financial difficulties.

**Expected credit loss for trade receivables:**

Based on internal assessment which is driven by the historical experience/ current facts available in relation to default and delays in collection thereof, the credit risk for trade receivables is considered low. The Company estimates its allowance for trade receivable using lifetime expected credit loss.



**Jubilant Biosys Limited**  
**Notes to the financial statements for the year ended 31 March 2024**  
**(All amounts are in INR lakhs unless otherwise stated)**

Company's exposure to credit risk for trade receivables using provisions matrix is as follows:

Particulars	As at 31 March 2024			As at 31 March 2023		
	Gross carrying amount	Allowance	Net carrying amount	Gross carrying amount	Allowance	Net carrying amount
Not due	4,160.94	3.28	4,157.66	4,923.55	-	4,923.55
0-90 days	2,436.18	2.36	2,433.82	2,934.79	-	2,934.79
90-180 days	449.39	0.39	449	1,294.66	-	1,294.66
180-270 days	131.01	4.09	126.92	669.58	-	669.58
270-360 days	27.83	16.7	11.13	118.72	0.63	118.09
More than 360 days	1,759.29	611.11	1,148.18	143.69	21.91	121.78
	<b>8,964.64</b>	<b>637.93</b>	<b>8,326.71</b>	<b>10,084.99</b>	<b>22.54</b>	<b>10,062.45</b>

Movement in the expected credit loss allowance of trade receivables are as follows:

Particulars	As at	As at
	31 March 2024	31 March 2023
Opening balance as of 1 April	22.54	22.54
Add: Provided for the year (net of reversal)	637.93	-
Less: Amount written off	(22.54)	-
<b>Balance at the year end</b>	<b>637.93</b>	<b>22.54</b>

*Expected credit loss on financial assets other than trade receivables:*

With regards to all financial assets with contractual cash flows other than trade receivable, management believes these to be high quality assets with negligible credit risk. The management believes that the parties from which these financial assets are recoverable, have strong capacity to meet the obligations and where the risk of default is negligible or nil and accordingly no provision for expected credit loss has been provided on these financial assets. Break up of financial assets other than trade receivables have been disclosed on balance sheet.

**(ii) Liquidity risk**

Liquidity risk is the risk that the Company will encounter difficulty in meeting the obligations associated with its financial liabilities that are settled by delivering cash or another financial asset. The Company's approach to managing liquidity is to ensure, as far as possible, that it will have sufficient liquidity to meet its liabilities when they are due, under both normal and stressed conditions, without incurring unacceptable losses or risking damage to the Company's reputation.

The management is responsible for managing the short term and long term liquidity requirements. Short term liquidity situation is reviewed daily by management. Longer term liquidity position is reviewed on a regular basis by the Board of Directors and appropriate decisions are taken according to the situation.

**Exposure to liquidity risk**

The following are the remaining contractual maturities of financial liabilities at the reporting date. The amounts are gross and does not include contractual interest payments.

As at 31 March 2024	Carrying amount	Contractual cash flows		
		Total	Within 1 year	More than 1 year
<b>Non-derivative financial liabilities</b>				
Borrowings	13,416.92	13,416.92	2,448.19	10,968.73
Lease Liabilities	3,880.16	3,880.16	1,118.39	2,761.77
Trade payables	2,587.04	2,587.04	2,587.04	-
Other financial liabilities	2,659.91	2,659.91	2,659.91	-
As at 31 March 2023	Carrying amount	Contractual cash flows		
		Total	Within 1 year	More than 1 year
<b>Non-derivative financial liabilities</b>				
Borrowings	18,846.91	18,846.91	3,725.00	15,121.91
Lease Liabilities	3,840.17	3,840.17	819.84	3,020.33
Trade payables	2,861.38	2,861.38	2,861.38	-
Other financial liabilities	2,931.41	2,931.41	2,931.41	-

Note:

- (i) Carrying amount represented as net of unamortised transaction cost.
- (ii) Contractual cash flows exclude interest payable.

**(iii) Market risk**

Market risk is the risk that changes in market prices – such as foreign exchange rates, interest rates and equity prices – will affect the Company's income or the value of its holdings of financial instruments. The objective of market risk management is to manage and control market risk exposures within acceptable parameters, while optimising the return.

**Currency risk**

The Company is exposed to currency risk to the extent that there is a mismatch between the currencies in which sales, purchases and borrowings are denominated and the respective functional currencies of Company companies. The currency in which the Company is exposed to risk are USD, EUR, GBP & others.



**Jubilant Biosys Limited**  
**Notes to the financial statements for the year ended 31 March 2024**  
(All amounts are in INR lakhs unless otherwise stated)

*Exposure to currency risk*

The summary quantitative data about the Company's exposure to currency risk as reported to the management of the Company is as follows:

Particulars	As at 31 March 2024				As at 31 March 2023			
	USD	EUR	GBP	Others	USD	EUR	GBP	Others
Trade receivables	8,304.33	57.18	-	-	9,540.79	146.67	-	-
Cash and cash equivalents	683.25	49.55	-	-	218.42	-	-	-
Trade payables	(930.58)	(38.17)	(34.55)	(47.93)	(1,422.88)	(21.21)	(4.39)	(29.98)
<b>Net statement of financial position exposure</b>	<b>8,057.00</b>	<b>68.56</b>	<b>(34.55)</b>	<b>(47.93)</b>	<b>8,336.33</b>	<b>125.46</b>	<b>(4.39)</b>	<b>(29.98)</b>

*Sensitivity analysis*

A reasonably possible strengthening (weakening) of the Euro, US Dollar or GBP against all other currencies at 31 March 2024 & 31 March 2023 would have affected the measurement of financial instruments denominated in a foreign currency and affected equity and profit or loss by the amounts shown below. This analysis assumes that all other variables, in particular interest rates, remain constant and ignores any impact of forecast sales and purchases.

Particulars	Other comprehensive income		Profit or loss before tax	
	Strengthening	Weakening	Strengthening	Weakening
<b>As at 31 March 2024</b>				
EUR (1% movement)	-	-	0.69	(0.69)
USD (1% movement)	-	-	80.57	(80.57)
GBP (1% movement)	-	-	(0.35)	0.35
Other(1% movement)	-	-	(0.48)	0.48
<b>As at 31 March 2023</b>				
EUR (1% movement)	-	-	1.25	(1.25)
USD (1% movement)	-	-	83.36	(83.36)
GBP (1% movement)	-	-	(0.04)	0.04
Other(1% movement)	-	-	(0.30)	0.30

**(iv) Interest rate risk**

Interest rate risk is the risk that fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates. The Company is exposed to interest rate risk because funds are borrowed at both fixed and floating interest rates. Interest rate risk is measured by using the cash flow sensitivity for changes in variable interest rate. The borrowing of the Company are principally denominated in INR with a mix of fixed and floating rates of interest. The Company has exposure to interest rate risk, arising principally on changes in base lending rate. The risk is managed by the Company by maintaining an appropriate mix between fixed and floating rate borrowings.

**Exposure to interest rate risk**

The interest rate profile of the Company's interest-bearing financial instruments as reported to management of the Company is as follows:  
The following table provides a break-up of the Company's fixed and floating rate borrowings:

**Note 32: Capital management**

**(a) Risk management**

The Company's objectives when managing capital are to:

- Safeguard their ability to continue as a going concern, so that they can continue to provide returns for shareholders and benefits for other stakeholders, and
- Maintain an optimal capital structure to reduce the cost of capital.

In order to maintain or adjust the capital structure, the Company may adjust the amount of dividends paid to shareholders, return capital to shareholders, issue new shares or sell assets to reduce debt. Consistent with others in the industry, the Company monitors capital on the basis of the following gearing ratio:

Net debt (total borrowings (excluding finance lease) net of cash and cash equivalents) divided by total 'equity' (as shown in the balance sheet).

The gearing ratios were as follows:

Particulars	As at	As at
	31 March 2024	31 March 2023
Net debt	10,255.13	18,381.66
Total equity	53,295.18	50,466.53
Net debt to equity ratio	0.19	0.36

**Note 33: Segment information**

An operating segment is a component that engaged in business activities of which it may earn revenues and incur expenses, including revenue and expenses that relate to transaction with any of the other components, as far as discrete financial information is available. This Company considered one business segment i.e. Drug Discovery services as the primary reporting segment on the basis that the risk and returns of the Company primarily determined by the nature of services. Chief operating decision maker of the Company is board, which reviewed the periodic result of the Company.

Based on the guiding principles given in the Ind AS 108 on "operating segments", as the Company's business activities fall within a single primary segment, the disclosure requirements of the said Ind AS 108 in this regard are not applicable.



**Jubilant Biosys Limited**

Notes to the financial statements for the year ended 31 March 2024

(All amounts are in INR lacs unless otherwise stated)

**Note 34: Related party disclosures****Name of the related parties**

Related parties where control exist

**i. Holding company**

Jubilant Pharmova Limited

**ii. Subsidiary company**

Jubilant Biosys Innovative Research Pte Limited

Jubilant Clinsys Limited

**iii. Fellow subsidiaries**

Jubilant Draximage Inc.

Jubilant Generics Limited

Jubilant Discovery Services LLC

Jubilant Phanna Holding Inc.

Jubilant Epicore LLC

Jubilant Epipad LLC

Jubilant Episcribe LLC

Jubilant Prodel LLC

Jubilant Therapeutics India Limited

Jubilant Therapeutics Inc.

**iv. Key management personnel**

Giuliano Perfetti - Chief executive officer and managing director

Prshant Kumar Deb - Whole time director

Saravanakumar Dhakshinamoorthy - Whole time director

Arvind Chokhany - Director

Gayatri Taragi - Director

Benny Thomas - Chief financial officer

Irfan Ali - Company secretary

**v. Others**

Jubilant Bhartia Foundation

Jubilant Ingrevia Limited

Jubilant Foodworks Limited

Jubilant Enpro Private Limited

**31 March 2024****Description of transactions**

S No.	Particulars	Holding/ Subsidiary/ fellow subsidiaries	Key management personnel	Others	Total
<b>1</b>	<b>Sale of services</b>				
	Jubilant Generics Limited	25.08	-	-	25.08
	Jubilant Ingrevia Limited	-	-	1.94	1.94
	Jubilant Epicore LLC	80.34	-	-	80.34
	Jubilant Epipad LLC	383.28	-	-	383.28
	Jubilant Episcribe LLC	155.91	-	-	155.91
	Jubilant Prodel LLC	25.89	-	-	25.89
	Jubilant Therapeutics Inc.	633.57	-	-	633.57
	Jubilant Draximage Inc.	45.3	-	-	45.3
<b>2</b>	<b>Purchase of goods and services</b>				
	Jubilant Ingrevia Limited	-	-	0.57	0.57
<b>3</b>	<b>Expenses recharged for facilities provided</b>				
	Jubilant Clinsys Limited	0.26	-	-	0.26
	Jubilant Discovery Services LLC	9.11	-	-	9.11
	Jubilant Pharmova Limited	1,102.32	-	-	1,102.32
	Jubilant Therapeutics India Limited	22.66	-	-	22.66
	Jubilant Ingrevia Limited	-	-	0.30	0.30
<b>4</b>	<b>Expenses recharged for cost sharing:</b>				
	Jubilant Pharmova Limited	4,674.55	-	-	4,674.55
	Jubilant Ingrevia Limited	-	-	682.29	682.29
	Jubilant Pharma Holding Inc.	123.18	-	-	123.18
	Jubilant Foodworks Limited	-	-	5.24	5.24



**Jubilant Biosys Limited**  
**Notes to the financial statements for the year ended 31 March 2024**  
**(All amounts are in INR lakhs unless otherwise stated)**

S No.	Particulars	Holding/ Subsidiary/ fellow subsidiaries	Key management personnel	Others	Total
<b>5</b>	<b>Expenses Charged by fellow subsidiaries</b>				
	Jubilant Discovery Services LLC	870.47	-	-	870.47
	Jubilant Generics Limited	25.64	-	-	25.64
	Jubilant Pharmova Limited	29.69	-	-	29.69
<b>6</b>	<b>Expenses Charged by other</b>				
	Jubilant Enpro Private Limited	-	7.35	-	7.35
<b>7</b>	<b>Remuneration and related expenses:</b>				
	Short term employment benefits	-	758.93	-	758.93
	Post employment benefits	-	31.02	-	31.02
<b>8</b>	<b>Interest on Inter Corporate Deposit</b>				
	Jubilant Pharmova Limited	703.8	-	-	703.8
	Jubilant Biosys Innovative Research Services Pte Limited	213.44	-	-	213.44
<b>9</b>	<b>Inter Corporate deposit given:</b>				
	Jubilant Biosys Innovative Research Services Pte Limited	2,491.35	-	-	2,491.35
<b>10</b>	<b>Inter Corporate deposit received back:</b>				
	Jubilant Biosys Innovative Research Services Pte Limited	8,250.00	-	-	8,250.00
<b>11</b>	<b>Security deposit given:</b>				
	Jubilant Pharmova Limited	100.00	-	-	100.00
<b>12</b>	<b>Donations:</b>				
	Jubilant Bhartia Foundation	-	-	225.40	225.40

**Amonnt outstanding**

S No.	Particulars	Holding/ Subsidiary/ fellow subsidiaries	Key management personnel	Others	Total
<b>13</b>	<b>Trade &amp; Other Payables</b>				
	Jubilant Discovery Services LLC	305.52	-	-	305.52
	Jubilant Ingrevia Limited	-	-	52.14	52.14
	Jubilant Generics Limited	0.91	-	-	0.91
	Jubilant Phanna Holding Inc.	8.52	-	-	8.52
	Jubilant Foodworks Limited	-	-	5.24	5.24
<b>14</b>	<b>Inter Corporate Deposit receivable</b>				
	Jubilant Pharmova Limited	7,900.00	-	-	7,900.00
	Jubilant Biosys Innovative Research Services Pte Limited	2,502.15	-	-	2,502.15
<b>15</b>	<b>Interest receivable</b>				
	Jubilant Biosys Innovative Research Services Pte Limited	79.48	-	-	79.48
<b>16</b>	<b>Trade Receivables:</b>				
	Jubilant Therapeutics Inc.	282.47	-	-	282.47
	Jubilant Epicore LLC	41.61	-	-	41.61
	Jubilant Epipad LLC	252.58	-	-	252.58
	Jubilant Episcibe LLC	85.21	-	-	85.21
	Jubilant Prodel LLC	2.64	-	-	2.64
	Jubilant Generics Limited	22.96	-	-	22.96
	Jubilant Ingrevia Limited	-	-	1.74	1.74



Jubilant Biosys Limited  
Notes to the financial statements for the year ended 31 March 2024  
(All amounts are in INR lakhs unless otherwise stated)

S No.	Particulars	Holding/ Subsidiary/ fellow subsidiaries	Key management personnel	Others	Total
<b>17 Other Recoverable:</b>					
	Jubilant Discovery Services LLC	4.46	-	-	4.46
	Jubilant Pharmova Limited	729.62	-	-	729.62
	Jubilant Therapeutics India Limited	8.64	-	-	8.64
	Jubilant Clinsys Limited	0.26	-	-	0.26
<b>18 Advance for supply of goods and services:</b>					
	Jubilant Pharmova Limited	497.46	-	-	497.46
<b>19 Security Deposit Assets:</b>					
	Jubilant Pharmova Limited	100.00	-	-	100.00

31 March 2023

Description of transactions

S No.	Particulars	Holding/ Subsidiary/ fellow subsidiaries	Key management personnel	Others	Total
<b>1 Sale of Services:</b>					
	Jubilant Generics Limited	64.69	-	-	64.69
	Jubilant Ingrevia Limited	-	-	0.21	0.21
	Jubilant Epicore LLC	434.63	-	-	434.63
	Jubilant Epipad LLC	716.38	-	-	716.38
	Jubilant Episcribe LLC	239.61	-	-	239.61
	Jubilant Prodel LLC	476.66	-	-	476.66
	Jubilant Therapeutics Inc.	1,173.78	-	-	1,173.78
	Jubilant Draximage Inc.	13.52	-	-	13.52
	Jubilant Pharmova Limited	8.62	-	-	8.62
<b>2 Purchase of goods and services</b>					
	Jubilant Ingrevia Limited	-	-	224.29	224.29
	Jubilant Pharmova Limited	9.71	-	-	9.71
<b>3 Purchase of fixed assets</b>					
	Jubilant Generics Limited	213.13	-	213.13	213.13
<b>4 Expenses recharged for facilities provided:</b>					
	Jubilant Clinsys Ltd	2.6	-	-	2.6
	Jubilant Discovery Services LLC	50.06	-	-	50.06
	Jubilant Pharmova Limited	664.88	-	-	664.88
	Jubilant Ingrevia Limited	-	-	0.78	0.78
	Jubilant Therapeutics India Limited	18.41	-	-	18.41
<b>5 Expenses recharged for Cost Sharing:</b>					
	Jubilant Pharmova Limited	3,541.72	-	-	3,541.72
	Jubilant Ingrevia Limited	-	-	261.02	261.02
<b>6 Expenses Charged by Fellow Subsidiaries</b>					
	Jubilant Discovery Services LLC	1,196.62	-	-	1,196.62
<b>7 Remuneration and related Expenses:</b>					
	Short term employment benefits	-	735.71	-	735.71
	Post employment benefits	-	28.12	-	28.12
<b>8 Interest on Inter Corporate Deposit</b>					
	Jubilant Pharmova Limited	592.55	-	-	592.55
	Jubilant Biosys Innovative Research Services Pte Limited	10.51	-	-	10.51
<b>9 Inter Corporate deposit given:</b>					
	Jubilant Biosys Innovative Research Services Pte Limited	8,250.00	-	-	8,250.00
<b>10 Donations:</b>					
	Jubilant Bhartia Foundation	-	-	191.00	191.00



**Jubilant Biosys Limited**  
**Notes to the financial statements for the year ended 31 March 2024**  
**(All amounts are in INR lakhs unless otherwise stated)**

S No.	Particulars	Holding/ Subsidiary/ fellow subsidiaries	Key management personnel	Others	Total
<b>Amount outstanding</b>					
<b>11</b>	<b>Trade &amp; Other Payables</b>				
	Jubilant Discovery Services LLC	191.79	-	-	191.79
	Jubilant Pharmova Limited	74.33	-	-	74.33
	Jubilant Ingrevia Limited	89.26	-	-	89.26
<b>12</b>	<b>Capital Creditor</b>				
	Jubilant Generics Limited	212.92	-	-	212.92
<b>13</b>	<b>Inter Corporate Deposit receivable</b>				
	Jubilant Pharmova Limited	7,900	-	-	7,900
	Jubilant Biosys Innovative Research Services Pte Limited	8,217	-	-	8,217
<b>14</b>	<b>Interest receivable</b>				
	Jubilant Biosys Innovative Research Services Pte Limited	10.51	-	-	10.51
<b>15</b>	<b>Trade Receivables:</b>				
	Jubilant Therapeutics Inc.	491.17	-	-	491.17
	Jubilant Epicore LLC	348.28	-	-	348.28
	Jubilant Epipad LLC	522.67	-	-	522.67
	Jubilant Episcribe LLC	92.93	-	-	92.93
	Jubilant Prodel LLC	235.88	-	-	235.88
	Jubilant Pharmova Limited	7.89	-	-	7.89
	Jubilant Ingrevia Limited	0.99	-	-	0.99
<b>16</b>	<b>Other Recoverable:</b>				
	Jubilant Discovery Services LLC	16.68	-	-	16.68
	Jubilant Pharmova Limited	432.48	-	-	432.48
	Jubilant Therapeutics India Limited	9.83	-	-	9.83

(Page left blank intentionally)



**Jubilant Biosys Limited**

Notes to the financial statements for the year ended 31 March 2024

(All amounts are in INR lakhs unless otherwise stated)

**Note 35: Contingent liabilities****Contingent liabilities to the extent not provided for:**

(i) Outstanding guarantees furnished by Banks on behalf of the Company are: INR 0.35 Lakhs (31 March 2023: INR 0.35 Lakhs).

**(ii) Claims against Company, disputed by the Company, not acknowledged as debt:**

The Company had entered into a lease agreement in September 2008 with AB Mallikarjuna (Landlord) for expanding its operation. Before occupying the property, certain legal lapses were identified and communicated to the landlord for corrective actions. However, no action had been taken by the landlord in due time hence the Company communicated its unwillingness to take the possession of the building and requested to refund the advance of INR 62 lakhs. As per clause 5 of the lease agreement the landlord's claimed lock in period rental for 36 months for INR 423.90 lakhs, the Company contested against the same. Hence, under Section 34 of the Arbitration and Conciliation Act, 1996 the landlord decided for arbitration award. The arbitrator concluded the award in July 2011 demanding INR 158.95 lakhs. The Company filed a cross objection in the Civil Court Bangalore in 2011 on the grounds of commercial occupancy certificate not provided by the landlord and the benefit received by the landlord during the impugned lock-in period as the premises had been occupied by another tenant during the period. The legal proceedings are in progress and management is of the view that the order will be given in favour of the Company.

**(iii) Other contingent liabilities:**

i. Interest on CENVAT credit wrongly availed and utilized by INR 17.13 Lakhs (Previous year INR 17.13 Lakhs) in FY 2020-21 based on the SCN No. 101/2019-20 dated 24/09/19 issued by the Deputy Commissioner, Central Tax, Audit

Name of the statute	Nature of dues	As at	
		31 March 2024	31 March 2023
Income tax act, 1961	Income tax	31,430.98	31,095.57
Goods and services tax act, 2017 (Rs. 0.24 paid under protest)	GST	1.11	2.71

The above does not include all other obligations resulting from claims, legal pronouncements having financial impact in respect of which the Company generally performs the assessment based on the external legal opinion and the amount of which cannot be reliably estimated.

**Note 36: Commitments at the end of the year****(i) Capital commitments**

Estimated amount of contracts remaining to be executed on capital account (Net of advances) is INR 940.33 Lakhs (31 March 2023: INR. 4,333.72 Lakhs).

**(ii) Other commitments**

The Company is a 100% Export Oriented Unit (EOU) therefore, the Company had to earn positive net foreign exchange over a period of 5 years in view of its recognition as 100% EOU under EOU Scheme 2015-20. However, the company has already achieved the positive net foreign exchange earnings.

**Note 37: Leases****(i) As a lessee**

The details of the right-of-use assets held by the Company is as follows:

	Depreciation charge for the year ended		Net carrying amount as at	
	31 March 2024	31 March 2023	31 March 2024	31 March 2023
Building	1,247.20	260.73	3,253.97	3,320.34
Land	27.17	22.64	2,748.69	2,597.06
Vehicles	28.51	25.90	77.81	95.08
	<b>1,302.88</b>	<b>309.27</b>	<b>6,080.47</b>	<b>6,012.48</b>

The movement in net carrying value of right-of-use assets of the Company:

	31 March 2024	31 March 2023
Net carrying value at the beginning of the year	6,012.48	4,708.88
Addition during the year	1,390.36	1,624.51
Deletion during the year (net of depreciation)	(19.49)	(11.64)
Depreciation during the year	(1,302.88)	(309.27)
Net carrying value at the end of the year	<b>6,080.47</b>	<b>6,012.48</b>

The movement in lease liabilities of the Company:

	31 March 2024	31 March 2023
Balance as at 1 April	3,840.17	2,822.03
Additions	1,211.56	1,906.81
Deletions	(21.47)	-
Finance costs	462.73	508.77
Repayment (including finance costs)	(1,612.83)	(1,397.44)
Balance as at 31 March	<b>3,880.16</b>	<b>3,840.17</b>



**Jubilant Biosys Limited**  
**Notes to the financial statements for the year ended 31 March 2024**  
(All amounts are in INR lakhs unless otherwise stated)

The aggregate maturities of long-term leases, based on contractual undiscounted cash flows are as follows:

	Less than 1 year	Between 1-5 years	More than 5 years	Total	Carrying value
<b>As at 31 March 2024</b>					
Lease liabilities	1,118.39	2,761.77	-	3,880.16	3,880.16
<b>As at 31 March 2023</b>					
Lease liabilities	819.84	2,440.06	580.27	3,840.17	3,840.17

Amount recognised in Statements of Profit or Loss:

	Year ended 31 March 2024	Year ended 31 March 2023
Interest on lease liabilities	462.73	508.77
Rental expense related to short-term lease	114.16	246.86
	<b>576.89</b>	<b>755.63</b>

Amount recognized in statement of cash flows:

	Year ended 31 March 2024	Year ended 31 March 2023
Total cash outflows for leases	1,150.11	888.65

(ii) As a lessor

Maturity analysis of lease payment

	Year ended 31 March 2024	Year ended 31 March 2023
Not later than one year	1.08	1.78
Later than one year, not later than two years	1.08	1.81
Later than two years, not later than three years	1.08	1.85
Later than three years, not later than four years	1.08	1.89

**Note 38: Earnings per share**

The calculation of profit attributable to equity shareholders and weighted average no. of equity shares outstanding for the purpose of basic and diluted earnings per share calculations are as follows:

	Year ended 31 March 2024	Year ended 31 March 2023
Profit for the year for basic earnings per share	2,853.33	9,339.82
Profit for the year for diluted earnings per share	2,853.33	9,339.82
Face value of the equity shares	10	10
Weighted average number of equity shares used in computing earnings per share		
<b>For basic earnings per share</b>		
No. of shares outstanding for whole year	Nos. 25,21,40,534	25,21,40,534
No. of shares for basic earnings per share	Nos. 25,21,40,534	25,21,40,534
<b>For diluted earnings per share:</b>		
No. of shares for basic earnings per share	Nos. 25,21,40,534	25,21,40,534
No. of shares for diluted earnings per share	Nos. 25,21,40,534	25,21,40,534
Earnings per share (face value of INR 10 each)		
Basic	INR 1.13	3.70
Diluted	INR 1.13	3.70

**Note 39: Disclosure pursuant to section 186(4) of the Companies Act, 2013 in respect of unsecured loans (refer note no. 34):**

	Purpose/ term of loan	31 March 2024	31 March 2023
<b>(i) Jubilant Pharmova Limited</b>			
Outstanding as at beginning of the year	General business purpose and interest rate @ 9.26% (Previous year 7.75%)	7,900.00	7,900.00
Given during the year		-	-
Repaid during the year		-	-
Outstanding as at end of the year		7,900.00	7,900.00
Maximum balance outstanding		7,900.00	7,900.00
<b>(ii) Jubilant Biosys Innovative Research Services Pte Limited</b>			
Outstanding as at beginning of the year	General business purpose and interest rate @ 9.30% (Previous year 9.30%)	8,250.00	-
Given during the year		2,491.35	8,250.00
Repaid during the year		8,250.00	-
Outstanding as at end of the year		2,502.15	8,250.00
Maximum balance outstanding		8,250.00	8,250.00



**Jubilant Biosys Limited**

Notes to the financial statements for the year ended 31 March 2024

(All amounts are in INR lakhs unless otherwise stated)

**Note 40: Ratios: -**

Ratio	Numerator	Denominator	31 March 2024	31 March 2023	% change	Reason for variance
Current ratio	Current Assets	Current Liabilities	1.66	1.49	11.65%	Refer (1) below
Debt-Equity ratio	Total Debt	Shareholder's Equity	0.25	0.37	-32.59%	Refer (2) below
Debt service coverage ratio	Earnings for debt service = Profit before tax + depreciation and amortisation expense + finance costs + exceptional items	Debt service = Finance costs + scheduled principal repayments (excluding prepayments) during the year for non-current borrowings (including current maturities) and lease liabilities	0.56	0.71	-21.27%	Refer (3) below
Return on equity ratio	Net Profits after taxes – Preference Dividend	Average Shareholder's Equity	5.50%	20.38%	-73.02%	Refer (3) below
Inventory turnover ratio	Revenue from operations	Average Inventory	63.70	134.27	-52.56%	Refer (4) below
Trade receivable turnover ratio	Net credit sales = Gross credit sales - sales return	Average Trade Receivable	4.90	6.02	-18.66%	Refer (4) and (5) below
Trade payable turnover ratio	Net credit purchases = Gross credit purchases - purchase return + other expense (net of non-cash and donations)	Average Trade Payables	8.12	8.19	-0.81%	Refer (6) below
Net capital turnover ratio	Revenue from operations	Average working capital = Average (current assets – current liabilities)	12.19	19.12	-36.28%	Refer (2) and (4) below
Net profit ratio	Net Profit	Net sales = Total sales - sales return	6.33%	17.14%	-63.06%	Refer (3) below
Return on capital employed	Earnings before interest and taxes	Capital Employed = Tangible Net Worth + Total Debt + Deferred Tax liability - Deferred tax assets	8.12%	19.98%	-59.38%	Refer (3) below
Return on investment	Net fair value gain/ (loss) + net gain/ (loss) on investment + dividend income	Average investments	-	-	-	Not applicable

**Notes:**

- (1) As at 31 March 2024, there has been an increase in project in progress included forming part of inventories compared to the last year.
- (2) Company has repaid the borrowings from the Hongkong and Shanghai Banking Corporation Limited during the current year.
- (3) Company's profit has been reduced in the current year due to decrease in revenue from operations.
- (4) Decrease in revenue from operations in the current year compared from the last year.
- (5) Decrease in trade receivables during the year.
- (6) Decrease in other expenses and purchases during the year.





**Jubilant Biosys Limited**

Notes to the financial statements for the year ended 31 March 2024

(All amounts are in INR lakhs unless otherwise stated)

**Note 41: Corporate social responsibility (CSR) expense**

	Year ended 31 March 2024	Year ended 31 March 2023
Amount required to be spent by the Company during the year	223.54	189.71
<b>Details of CSR spent during the financial year*</b>		
a) On construction / acquisition of any asset	-	-
b) On purposes other than (a) above	225.40	191.00
Shortfall at the end of the year	-	-
Total of previous years shortfall	-	-
Reason for shortfall		

\*Included in donation – Refer note 34

The Company's CSR activities primarily focus on programs relating to improving health indices through innovative services and promoting health seeking behavior, universalising elementary education and improving quality parameters for primary education through community involvement, enhancing employability through vocational training and supporting local infrastructure development.

**Note 42:** The Company has established a comprehensive system of maintenance of information and documents as required by the transfer pricing legislation under sections 92-92F of the Income-tax Act, 1961. Since the law requires existence of such information and documentation to be contemporaneous in nature, the Company is in the process of updating the documentation for the specified domestic transactions entered into with the specified persons and the international transactions entered into with the associated enterprises during the financial year and expects such records to be in existence before the due date of filing of income tax return. The management is of the opinion that its specified domestic transactions and international transactions are at arm's length so that the aforesaid legislation will not have any impact on the financial statements, particularly on the amount of tax expense and that of provision for taxation.

**Note 43:** The Company has foreign currency receivables aggregating to INR 1,775.44 lakhs (31 March 2023: 216.39 lakhs) which are outstanding for more than nine months as at 31 March 2024 and foreign currency payables aggregating to INR 32.05 lakhs (31 March 2023: 46.76 lakhs) which are outstanding for more than six months as at 31 March 2024. The Company is in the process of applying to its authorised dealer bank for extension of time for receipt and payment of above-mentioned receivables and payables respectively.

**Note 44: Reporting on audit trail**

The Ministry of Corporate Affairs (MCA) has prescribed a new requirement for companies under the proviso to Rule 3(1) of the Companies (Accounts) Rules, 2014 inserted by the Companies (Accounts) Amendment Rules 2021 requiring companies, which uses accounting software for maintaining its books of account, shall use only such accounting software which has a feature of recording audit trail of each and every transaction, creating an edit log of each change made in the books of account along with the date when such changes were made and ensuring that the audit trail cannot be disabled.

The Company has used accounting software for maintenance of all accounting and payroll records. The audit trail (edit logs) feature for any direct changes made at the database level of such accounting software was not enabled to log any direct data changes for the period 1 April 2023 to 30 November 2023. However, the audit trail (edit logs) at the application level for the accounting software was operating for all relevant transactions recorded in the software.

**Note 45: Assets pledged as security**

Assets with following carrying amounts are pledged as security against borrowings from bank:

	As at 31 March 2024	As at 31 March 2023
<b>Non current assets</b>		
<b>First charge</b>		
Property, plant and equipment	22,209.73	14,559.47
<b>Total non current assets pledged as security</b>	<b>22,209.73</b>	<b>14,559.47</b>
<b>Current assets</b>		
<b>First charge</b>		
Inventories	1,231.72	187.26
Trade receivables	8,326.71	10,062.45
Cash and cash equivalents	3,161.79	465.25
Loans	62.21	66.80
Other financial assets	1,433.54	1,306.64
Other current assets	4,420.15	5,301.63
<b>Total current assets pledged as security</b>	<b>18,636.12</b>	<b>17,390.03</b>



**Jubilant Biosys Limited**

Notes to the financial statements for the year ended 31 March 2024

(All amounts are in INR lakhs unless otherwise stated)

**Note 46: Additional information**

1. There are no funds which have been advanced or loaned or invested (either from borrowed funds or share premium or any other sources or kind of funds) by the Company to or in any other persons or entities, including foreign entities ("Intermediaries"), with the understanding, whether recorded in writing or otherwise, that the Intermediary shall directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever ("Ultimate Beneficiaries") by or on behalf of the Company or Provide any guarantee, security or the like to or on behalf of the Ultimate Beneficiaries, Except that during the year the Company loaned USD 3 million (INR 2491.35 lakhs) to Jubilant Biosys Innovative Research Services Pte. Ltd., its wholly owned subsidiary, on 14 August 2023 which was further loaned to Drug Discovery and Development Solutions Limited, fellow subsidiary of the Company, on 17 August 2023 which was invested in Jubilant Therapeutics Inc., a fellow subsidiary of the Company, on 17 August 2023 which was ultimately invested in Jubilant Episcrite LLC, Jubilant Epicore LLC, Jubilant Epipad LLC and Jubilant Prodel LLC, wholly owned subsidiaries of Jubilant Therapeutics Inc, in multiple tranches during the year. The Company has complied with relevant provisions of the Foreign Exchange Management Act, 1999 (42 of 1999), to the extent applicable, the Companies Act, 2013 for such transaction and this transaction is not violating of the Prevention of Money Laundering Act, 2002 (15 of 2003).

2. There are no funds which have been received by the Company from any persons or entities, including foreign entities ("Funding Parties"), with the understanding, whether recorded in writing or otherwise, that the Company shall:

(i) directly or indirectly, lend or invest in other persons or entities identified in any manner whatsoever ("Ultimate Beneficiaries") by or on behalf of the Funding Party or

(ii) Provide any guarantee, security or the like from or on behalf of the Ultimate Beneficiaries.

3. No proceeding has been initiated or pending against the Company for holding any benami property under the Benami Transactions (Prohibition) Act, 1988 (45 of 1988) and rules made thereunder.

4. The Company has not been declared as willful defaulter by any bank or financial institution or other lender.

5. There is no transactions with companies struck off under section 248 of the Companies Act, 2013 or section 560 of the Companies Act, 1956 during the current financial year.

6. There are no transaction which has been surrendered or disclosed as income during the year in the tax assessments under the Income Tax Act, 1961.

7. There are no charges or satisfaction yet to be registered with ROC beyond the statutory period.

8. The Company (as per the provisions of the Core Investment Companies (Reserve Bank) Directions, 2016) does not have any Core Investment Company.

9. There are no reportable events post the year end.


The accompanying notes form an integral part of the Financial Statements

As per report of even date attached.

For Walker ChandioK & Co LLP

Chartered Accountants

Firm registration number: 001076N/N500013



Nifin Toshniwal  
Partner

Membership No: 507568

Place: Noida

Date: 28 May 2024



For and on behalf of Board of Directors of  
Jubilant Biosys Limited



Giuliano Perfetti  
Chief Executive Officer and  
Managing Director  
DIN: 09357368  
Place: Noida  
Date: 28 May 2024



Irfan Ali  
Company Secretary  
Place: Noida  
Date: 28 May 2024




Prasant Kumar Deb  
Whole Time Director

DIN: 09187850

Place: Noida

Date: 28 May 2024



Benny Thomas  
Chief Financial Officer  
Place: Bengaluru  
Date: 28 May 2024